Compound screening methods

ABSTRACT

The invention provides methods of screening for compounds which affect the activity of a physiologically important calcium pump, the sarco/endoplasmic reticulum Ca 2+  ATPase (SERCA), using the nematode worm  C. elegans.

RELATED APPLICATIONS

[0001] This application is a divisional of application Ser. No.09/549,872 filed Apr. 14, 2000, now pending. This application claimspriority under Title 35 U.S.C. §119(e), of U.S. provisional applicationNo. 60/129,596, filed Apr. 15, 1999, entitled COMPOUND SCREENINGMETHODS, and foreign priority benefits under Title 35, U.S.C.,§119(a)-(d) or §365(a),(b) of foreign patent application. Nos. GB9908670.4, filed Apr. 15, 1999, & GB 9912736.7, filed Jun. 1, 1999, theentire contents of which are incorporated herein by reference.

SPECIFICATION

[0002] The invention is concerned with methods for use in theidentification of compounds which affect the activity of aphysiologically important calcium pump, the sarco/endoplasmic reticulumCa²+ATPase (SERCA).

[0003] In most animal cells and plant cells, the normal concentration offree cytosolic Ca²⁺ is 50 to 100 nM. Since Ca²⁺ acts as a majorintracellular messenger, elevating these levels affects a wide range ofcellular processes including contraction, secretion and cell cycling(Dawson, 1990, Essays Biochem. 25:1-37; Evans et al., 1991, J. Exp.Botany 42:285-303). Intracellular Ca²⁺ stores hold a key position in theintracellular signalling. They allow the rapid establishment of Ca²⁺gradients, and accumulate and release Ca²⁺ in order to control cytosolicCa²⁺ levels. Moreover, lumenal Ca²⁺ intervenes in the regulation of thesynthesis, folding and sorting of proteins in the endoplasmic reticulum(Brostrom and Brostrom, 1990, Ann. Rev. Physiol. 52:577-590; Suzuki etal., 1991, J. Cell. Biol. 114:189-205; Wileman et al., 1991, J. Biol.Chem. 266:4500-4507). Furthermore it controls signal-mediated andpassive diffusion through the nuclear pore (Greber and Gerace, 1995, J.Cell. Biol. 128:5-14).

[0004] Three genes that code for five different isoforms of thesarco/endoplasmic reticulum Ca²⁺ ATPase (SERCA) are known invertebrates, SERCA1a/b, SERCA2a/b and SERCA3. The SERCA isoforms areusually tagged to the endoplasmic reticulum (ER) or ER subdomains likethe sarcoplasmic reticulum, although the precise subcellular location isoften not known. The SERCA proteins belong to the group of ATP-drivenion-motive ATPases, which also includes, amongst others, the plasmamembrane Ca²⁺-transport ATPases (PMCA), the Na+-K+-ATPases, and thegastric H+-K+-ATPases. The SERCA Ca²⁺-transport ATPases can bedistinguished from their plasma membrane counterparts like PMCA by thespecific SERCA inhibitors: thapsigargin, cyclopiazonic acid, and2,5-di(tert-butyl)-1,4-benzohydroquinone (Thastrup et al., 1990, PNAS87:2466-2477; Seidler et al., 1989, J. Biol. Chem. 264:17816-17823;Oldershaw and Taylor, 1990, FEBS Lett. 274:214-216). In view of thediverse role of Ca²⁺ in the cell and the fact that Ca²⁺ is stored indiverse organelles, the diversity in Ca²⁺-accumulation pump isoforms isnot surprising.

[0005] SERCA1 is only expressed in fast-twitch skeletal muscle fibres.The gene encodes two different isoforms; SERCA1b which is the neonatalisoform and SERCA1a the adult isoform (Brandl et al., 1986, Cell44:597-607; Brandl et al., 1987, J. Biol. Chem. 262:3768-3774). Thedifference between the two isoforms is the result of an alternativesplice. As a consequence, the neonatal isoform contains a highly chargedcarboxyl-terminal extension (Korczak et al., 1988, J. Biol. Chem.263:4813-4819). The reason for this alternative splicing is as yetunknown; the functional significance of this extension is not yet clear.When expressed in COS cells, SERCA1a and SERCA1b exhibit nearlyidentical maximal Ca²⁺-turnover rate, Ca²⁺-affinity and ATP-dependencyof Ca²⁺ transport (Maruyama and MacLennan, 1988, PNAS 85:3314-3318). Thehuman SERCA1 gene is mapped on chromosome 16P12.1 and is about 26 kblong (MacLennan et al., 1987, Somatic Cell Mol. Genet. 13:341-346;Callen et al., 1991, Am. J. Hum. Genet. 49:1372-1377).

[0006] SERCA2 is expressed in muscle and non-muscle cells. The humanSERCA2 gene maps to chromosome 12q23-q24.1 (Otsu et al., 1993, Genomics17:507-509). Partial sequence analysis suggests that the sameexon/intron layout is conserved between SERCA1 and SERCA2. mRNA ofSERCA2 can be divided in 4 different classes; class 1 encodes SERCA2aand is mainly expressed in muscle, the other classes encode SERCA2b andare mainly expressed in non-muscle tissues. SERCA2b harbors a 49 aminoacid extension, which contains a highly hydrophobic stretch. As withSERCA1, no functional difference can be measured between the two SERCA2isoforms when expressed in COS cells (Campbell, 1991, J. Biol. Chem.266:16050-16055). However, differences in Ca²⁺ affinity and turnoverrate of the phosphoprotein intermediate have been observed (Lytton etal., 1992, 267:14483-14489; Verboomen et al., 1992, J. Biochem.286:591-596). Both isoforms are expressed in a tissue-dependent pattern,both qualitatively and quantitatively (Eggermont et al., 1990, J.Biochem. 271:649-653). Cardiac muscle expresses 5- to 20-fold higherlevels of SERCA2 than smooth muscle. Slow-twitch skeletal and cardiacmuscle only express SERCA2a, while SERCA2b (referred to as the“housekeeping” isoform) is expressed in all non-muscle tissue, andrepresents about 75% of the Ca²⁺-transporting ATPase activity insmooth-muscle tissue. Different protein-to-message ratios for SERCA2aand SERCA2b have been observed. Cardiac muscle expresses 70 times moreprotein and only 7 times more SERCA2a mRNA compared to stomach smoothmuscle which expresses SERCA2b (Khan et al., 1990, J. Biochem.268:415-419).

[0007] SERCA3 is considered to be the non-muscle SERCA isoform. SERCA3lacks the putative interacting domain for phospholamban, and hence, doesnot respond to this modulator (Toyofuku et al., 1993, J. Biol. Chem.268:2809-2815). When expressed in COS cells, SERCA3 shows approximately5-fold lower activity for Ca²⁺ and a slightly higher pH optimum(Toyofuku et al., 1992, J. Biol. Chem. 267:14490-14496). In platelets,mast cells and lymphoid cells SERCA3 is co-expressed with SERCA2b(Wuytack et al., 1994, J. Biol. Chem. 269:1410-1416; Wuytack et al.,1995, Bioscience Rep. 15:299-306). Expression has also been observed insome arterial endothelial cells, in early developing rat heart, in somesecretory epithelial cells of endodermal origin and in cerebellarPurkinje neurons.

[0008] In slow-twitch skeletal muscle, cardiac muscle and smooth-muscletissues, SERCA2 activity is modulated by phosphorylation of theregulatory protein phospholamban (PLB) (see Fuji et al., 1991, FEBSLett. 273:232-234). In cardiac muscle, in vivo phosphorylation of PLB bycAMP- or Ca²⁺/Calmodulin-dependent protein kinase has a positive effecton the Ca²⁺ transport (Le Peuch et al., 1997, Biochemistry 18:5150-5157;Tada et al., 1979, J. Biol. Chem. 254: 319-326; Davis et al., 1983, J.Biol. Chem. 258:13587-13591; Wegener et al., 1989, J. Biol. Chem.264:11468-11474). In order to determine the exact in vivo role ofphospholamban, PLB-deficient mice have been generated (Luo et al., 1994,Circ. Res. 75:401-409). A marked effect is observed on Ca²⁺ uptake,whereas no effect is measured in Vmax. The ablation of the PLB gene inmice is associated with increased myocardial contractility, and a lossof the positive inotropic response to δ-adrenergic stimulation. Theprecise molecular mechanism underlying the modulation of SERCA by PLB isnot apparent. An electrostatic mechanism has been proposed, as a directinteraction between PLB and SERCA, in which the unphosphorylated PLBinhibits the SERCA pump (Kirchberger et al., 1986, Biochemistry25:5484-5492; Chiesi and Schwaller, 1989, FEBS Lett. 244:241-244; Xu andKirchberger, 1989, J. Biol. Chem. 264:16644-16651). Alternatively, PLBand the SERCA Ca²⁺ pump are able to interact and phosphorylation of PLBalters its properties, as confirmed by cross-linking experiments (Jameset al., 1989, Nature 342:90-92). In some experiments, inhibitory effectsof PLB have been observed on co-transfection of PLB and SERCA2a in COS-1cells (Fuji et al. 1990, FEBS Lett. 273:232-234). Several models havebeen proposed to explain the regulatory effect of PLB on Ca²⁺ ATPases.These include the aggregation of SERCA2 around a pentameric form of PLB(Voss et al., 1994, Biophys J. 67:190-196). Another explanation startsfrom the electrostatic inhibition of Ca²⁺ binding due to the SERCA-PLBinteraction (Toyofuku et al., 1994, J. Biol. Chem. 269:3088-3094). Theinteraction between PLB and SERCA2a has been studied in more detail,revealing a putative PLB binding domain that is also present SERCA1 butnot in SERCA3. This has been further confirmed by expression studies inCOS-1 cells (Toyofuku et al., 1993, J. Biol. Chem., 268:2809-2815). Sucha finding is remarkable as SERCA1 and PLB are never co-expressed invivo.

[0009] Direct phosphorylation of SERCA by Ca²⁺/CaM kinase II results ina 2-fold higher maximal velocity Xu and Kirchberger, 1989, J. Biol.Chem. 264: 16644-16651. This CaM kinase phosphorylation is specific forSERCA2 and may act synergistically with the phosphorylation ofphospholamban.

[0010] Sarcolipin (SLN) is a peptide of 33 amino acids in length thatco-purifies with SERCA1. The human gene encoding SLN was mapped tochromosome 11q22-q23. The protein sequence shows some homology tophospholamban, especially in the lumenal part of the protein. In rabbitsSLN is highly expressed in fast-twitch skeletal muscle, as is SERCA1(Odermatt et al., 1997, Genomics 45:741-553). In co-expression studiesin HEK-293 T-cells, a decrease of SERCA1 affinity for Ca²⁺ was observed,but maximal Ca²⁺ uptake rates were stimulated. Mutational analysisprovided evidence for different mechanisms of interaction of both SLNand PLB with the SERCA molecules (Odermatt, et al., 1998, J. Biol. Chem.273:12360-12369).

[0011] SERCA plays an important role in regulating Ca²⁺ levels, andhence in pathologies related to abnormal Ca²⁺ concentrations andregulation. For instance, abnormal cytosolic free Ca²⁺ levels areinvolved in different muscle pathologies (Morgan, 1991, N. Engl. J. Med.325:625-632; Perreault et al., 1993, Circulation 87 Suppl. VII:31-37).Other major pathologies in which SERCA may play a role include cardiachypertrophy, heart failure, and hypertension (Arai et al., 1994, Circ.Res. 74:555-564; Lompré et al., 1994, J. Mol. Cell. Cardiol.26:1109-1121).

[0012] Cardiac hypertrophy is an adaptive response of the cardiac muscleto a hemodynamic overload, in which diastolic dysfunction is one of theearliest signs of pathological hypertrophic response. In animal models,where most studies are performed, a highly significant positivecorrelation has been obtained between end-diastolic cytosolic Ca²⁺levels and diastolic relaxation abnormalities. After aortic binding,SERCA2 mRNA and protein levels are decreased, as is the sarcoplasmicreticulum Ca²⁺ uptake (Komuro et al., 1989, J. Clin Invest.83:1102-1108; de la Bastie et al., 1990, Circ. Res. 66:554-564). Thiseffect was only found in cases of severe hypertrophy, and was onlyobserved when heart failure occurs. In moderate hypertropy and in casesof compensated hypertrophy no changes in the level of SERCA mRNA wereobserved (de la Bastie et al, ibid; Feldman et al., 1993, Circ. Res.73:184-192).

[0013] In humans, most studies report a decrease in SERCA2 mRNA, SERCA2protein levels and decreased Ca²⁺ uptake in a failing heart (Arai etal., 1993, Circ. Res. 72:463-469; Hasenfuss et al., 1994, Circ. Res.,75: 434-442). The decreased levels of SERCA2 expression are accompaniedby decreased expression of phospholamban, cardiac ryanodine receptor anddihydropyridine receptor (Vatner et al., 1994, Circulation 90:1423-1430;Go et al., 1995, J. Clin. Invest. 95:888-894; Takahashi et al., 1992, J.Clin. Invest. 90:927-935). These human heart failure data are confirmedin different animal models. In a hypertrophic animals, SERCA2 expressionlevels are decreased; in a dilated strain Ca²⁺ uptake is decreased withincreasing age (Kuo et al., 1992, Biochem Biophys acta 1138:343-349;Whitmer et al., 1988, Circ. Res. 62:81-85). Most striking in both humansand animal models is the strong positive correlation between SERCA2 andphospholamban mRNA levels. Examples in literature that do not confirmthese data are most likely the result of various pathogenic mechanismsthat can lead to heart failure.

[0014] Blood vessels from hypertensive animals have an increased wallthickness and show altered contractile properties. Several lines ofevidence indicate that diminished Ca²⁺ pump activities might contributeto elevation in cytoplasmic Ca²⁺ levels in hypertension. However,increased expression of SERCA2 has also been observed. Further study isrequired to resolve these contradictory results.

[0015] Darier-White disease is an autosomal-dominant skin disordercharacterized by loss of adhesion between epidermal cells (acantholysis)and abnormal keratinization. In several patients mutations have beenfound in SERCA2, demonstrating the role of SERCA and Ca²⁺-signallingpathway in the regulation of cell-to-cell adhesion and differentiationof the epidermis (Sakuntabhai et al., 1999, Nature Genetics 21:271-277).

[0016] Although little is known about the involvement of SERCA inskeletal muscle disorders, deficiency in the Ca²⁺-transport ATPaseactivity has been found in Brodys disease (Benders et al., 1994, J.Clin. Res. 94:741-748). The disorder is characterized byexercise-induced impairment of muscle relaxation. Normal levels ofSERCA1 protein were detected, but the SERCA activity was decreased byabout 50% in patients suffering from the disease. In other research,SERCA1 in fast-twitch fibers of Brody patients could not be detectedimmunologically (Danon et al., 1988, Neurology 38:812-815). However,three Brody patients show no defects in their SERCA1 gene, indicatingpleiotropic mechanisms underlying Brody disease (Zhang et al., 1995,Genomics 30:415-424).

[0017] The underlying mechanism of non-insulin-dependent diabetesmellitus (NIDDM) is still unknown. In islets of Lagerhans from db/dbmice (a NIDDM model), glucose-induced initial induction and subsequentoscillations of intracellular Ca²⁺ concentrations were absent. Furtheranalysis showed that SERCA3 was almost entirely lacking from the db/dbislets. These results and thapsigargin experiments implicate SERCA3 inthe defective insulin secretion associated with NIDDM (Roe et al., 1994,J. Biol. Chem. 269:18279-28282). A significant reduction of SERCA3expression was also found in Goto-Kakizaki rats, a non-obese model ofNIDDM (Varadi et al., 1996, J. Biochem. 319:521-527) Interactions havebeen reported between different SERCAs (SERCA1 and SERCA2) and differentInsulin Receptor Substrates (IRS-1 and IRS-2). This interaction wasdependant on insulin (Algenstaedt et al., 1997, J. Biol. Chem.272:23696-23702). Inactivation of IRS-2 has recently been shown toresemble certain aspects of type 2 diabetes (Withers et al., 1998,Nature 391:900-904).

[0018] In mammals, there are three genes encoding different SERCAisoforms. In contrast, the nematode worm Caenorhabditis elegans (C.elegans) has only a single homologue of the mammalian SERCA protein,which was identified by the C. elegans genome-sequencing consortium (seeScience issue 282, 1998). The C. elegans SERCA gene is located onchromosome III on a cosmid named K11D9. On a physical level, the geneconsists of six exons that span an Open Reading Frame of 3.2 kb,resulting in a predicted protein of 1059 amino acids. The consensusalternative splice site that is present in the C-terminal end ofmammalian SERCA genes is present in the worm as well. This leads to asecond isoform consisting of 7 exons that span an ORF of 3.0 kb,resulting in a protein of 1004 amino acids. This may indicate afunctional conservation of this domain of the protein, e.g. inregulating the activity of the SERCA pump.

[0019]C. elegans is a small roundworm that has a life span of only threedays, allowing rapid accumulation of large quantities of individualworms. The cell-lineage is fixed, allowing identification of each cellwhich has the same position and developmental potential in eachindividual animal. C. elegans is extremely amenable to geneticapproaches and a large collection of mutants have been isolated that aredefective in embryonic development, behaviour, morphology, neurobiologyetc. There is also a large cosmid collection covering almost the wholeC. elegans genome, which is used to determine the complete genomicsequence of the worm.

[0020] These characteristics of C. elegans make it the organism ofchoice for use as a tool in the drug discovery process. In particular,C. elegans may be used in the development of high throughput live animalcompound screens, useful in the development of potential candidatedrugs, in which worms are exposed to the compound under test and anyresultant phenotypic and/or behavioural changes are recorded. Thepresent inventors have developed a number of C. elegans-based screeningmethods which may be used to identify compounds which modulate theactivity of SERCA, either directly or via the SERCA/PLB interaction.Compounds identified as modulators of SERCA activity using thesescreening methods may be useful as pharmaceuticals in the treatment ofthe wide range of diseases with which the SERCA genes have beenassociated.

[0021] Accordingly, in a first aspect the invention provides a method ofidentifying compounds which are capable of enhancing or up-regulatingthe activity of a sarco/endoplasmic reticulum calcium ATPase, whichmethod comprises:

[0022] contacting C. elegans which exhibit reduced SERCA ATPase activitycompared to wild type C. elegans in one or more cell types or tissueswith a compound under test; and

[0023] detecting a phenotypic, biochemical or behavioural change in theC. elegans indicating a reversion towards wild type SERCA activity inthe one or more cell types or tissues which exhibit reduced SERCAactivity in the absence of the compound.

[0024] The method of the invention, which will be hereinafter referredto as the ‘up-regulation assay’ is performed using a C. elegans strainwhich exhibits reduced SERCA ATPase activity in one or more cell typesor tissues, as compared to the SERCA ATPase activity in wild-type C.elegans. It has been observed that worms which exhibit reduced SERCAactivity compared to wild-type worms manifest a variety of phenotypicand behavioural defects. The basis of the up-regulation assay istherefore to take worms which exhibit defects due to reduced SERCAactivity, contact these worms with the compound under test and screenfor phenotypic, behavioural or biochemical changes indicating areversion towards wild-type SERCA activity. For example, worms withreduced SERCA activity often show a reduction in the rate of pharynxpumping. In this case, screening for an increase in the rate of pharynxpumping in the presence of a test compound would indicate a reversiontowards wild-type SERCA activity due to the ability of the compound toenhance or up-regulate SERCA. For comparison purposes, an example of aC. elegans strain which exhibits ‘wild-type’ SERCA activity is the N2strain (this strain can be obtained from CGC, University of Minnesota,USA). The N2 strain has been particularly well characterised in theliterature with respect to properties such as pharynx pumping rate,growth rate and egg laying capacity (see Methods in Cell Biology, Volume48, Caenorhabditis elegans: Modern biological analysis of an organism,ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; Thenematode Caenorhabditis elegans, ed. by William Wood and the communityof C. elegans researchers., 1988, Cold Spring Harbor Laboratory Press;C. elegans II, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J.Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press.).

[0025]C. elegans which exhibit reduced SERCA activity in one or morecell types or tissues can be obtained in several different ways. In afirst embodiment, worms with reduced SERCA activity are obtained bytreating a culture of worms with a chemical inhibitor of SERCA such as,for example, thapsigargin. As will be demonstrated in the examples givenherein, treatment of C. elegans with thapsigargin results inrecognisable phenotypic and behavioural changes such as paleness,reduced growth, pharynx pumping defects and production of very fewprogeny which are sick and grow very slowly. Accordingly, reversion ofany one of these characteristics towards wild-type can provide anindication of a reversion towards wild-type SERCA activity.

[0026] In another embodiment, worms with reduced SERCA activity can beproduced by specifically down-regulating the expression of SERCA in oneor more tissues using antisense techniques or double stranded RNAinhibition. This can be achieved by transfection of C. elegans with avector that expresses either an antisense C. elegans SERCA RNA or doublestranded C. elegans SERCA RNA. Specific down-regulation of SERCAexpression in different cell types or tissues of the worms can beachieved by incorporating into the vector an appropriate tissue-specificpromoter to drive expression of the antisense RNA or double stranded RNAin the required tissues. SERCA expression will be specificallydown-regulated only in those tissues which express the antisense RNA ordouble stranded RNA. By way of example, the promoter region of the C.elegans SERCA gene itself (see the examples given below) can be used todirect expression of an antisense RNA or double stranded RNA in all thecells and tissues which express SERCA. The C. elegans myo-2 promoter canbe used to direct expression in the pharynx. The C. elegans myo-3promoter can be used to direct expression in the body wall muscles. Theuse of antisense and double stranded RNA inhibition will be furtherunderstood with reference to the Examples included herein.

[0027] Alternative RNAi techniques which may be used to inhibit SERCAactivity are described in the applicant's co-pending Internationalpatent application No. WO 00/01846. These techniques, which are based ondelivery of dsRNA to C. elegans by feeding with an appropriate dsRNA orfeeding with food organisms which express an appropriate dsRNA, may leadto a more stable RNAi phenotype than results from injection of dsRNA.

[0028] In a still further embodiment, the C. elegans exhibiting reducedSERCA ATPase activity in one or more cell types or tissues may be amutant strain in which SERCA activity is reduced but not eliminated i.e.a reduction-of-function mutant. The mutation may give rise to reducedSERCA activity through a down-regulation of SERCA expression in one ormore cell types or tissues or through a defect in the SERCA proteinitself or a defect in regulation of the activity of the SERCA protein.

[0029] A reduction-of-function mutant or a knock-out mutant can beisolated using a classical non-complementation screen, starting with aheterozygote C. elegans strain carrying a mutant SERCA allele on onechromosome and a recessive marker close to the wild-type SERCA allele onthe other chromosome. The worms are subjected to mutagenesis usingstandard techniques (EMS or UV-TMP are suitable for this purpose) andthe progeny is screened by eye for defects, especially in tissues whichexpress SERCA. Since the screening is performed in the F1 generation,mutations will only give rise to a phenotype if the mutation occurs inthe SERCA gene (due to non-complementation) or if the mutation isdominant, which does not occur frequently. These two possibilities canbe distinguished in subsequent generations. A newly introduced SERCAmutation should be linked to the recessive marker. As a further control,DNA sequencing can be performed to determine the nature of the mutation.

[0030] The step of ‘detecting a phenotypic, biochemical or behaviouralchange in the C. elegans indicating a reversion towards wild type SERCAactivity’ may be performed in several different ways. The method ofchoice is generally dependent upon the phenotype/behaviouralcharacteristics of the starting worm strain, which is in turn generallydependent upon the nature of the cell types or tissues in which SERCAactivity is reduced.

[0031] Inhibition experiments, for example the RNAi experiments andthapsigargin experiments described herein, demonstrate that SERCA is avital protein for C. elegans. Moreover, reduction of SERCA activityresults in a variety of phenotypes that can be used as basis of an assayto isolate compounds that alter the activity of SERCA. The main defects,and hence phenotypes, associated with reduced SERCA activity are relatedto muscle function e.g pharyngeal muscle, body wall muscle, vulvamuscle, anal repressor muscle, and anal sphincter muscle. Screens basedon reversion of defects in these muscles to wild-type can be used toidentify compounds and genes that alter the activity of SERCA. Moreover,other phenotypes, such as paleness, reduced growth, reduced progeny,protruding vulva and protruding rectum can be used to identify compoundsand genes that alter the function of SERCA.

[0032] In one embodiment, particularly suitable for use when thestarting worm strain exhibits defects in pharynx pumping due to reducedSERCA activity in the pharynx (as compared to wild-type C. elegans) theup-regulation assay can be based on detection of changes in the pharynxpumping efficiency. If the starting worm strain exhibits a reduced rateof pharynx pumping due to reduced SERCA activity in the pharynx, then anincrease in the rate of pharynx pumping in the presence of a testcompound can be used as an indicator of a reversion towards wild-typeSERCA activity in the pharynx.

[0033]C. elegans feeds by taking in liquid containing its food (e.g.bacteria). It then spits out the liquid, crushes the food particles andinternalises them into the gut lumen. This process is performed by themuscles of the pharynx. The process of taking up of liquid andsubsequently spitting it out, requiring contraction and relaxation ofmuscles, is called pharyngeal pumping or pharynx pumping.

[0034] Alterations in SERCA activity influence the pharyngeal pumpingrate. In particular, inhibition of SERCA using thapsigargin causes areduction in the rate of pharynx pumping. Measurement of the pumpingrate of the C. elegans pharynx is hence a method to determine theactivity of SERCA. The pharynx pumping efficiency can be convenientlymeasured by placing the nematodes in liquid containing a fluorescentmarker molecule precursor, such as calcein-AM. Calcein-AM present in themedium is taken up by the nematodes and the AM moiety is cleaved off bythe action of esterases present in the C. elegans gut, resulting in theproduction of the fluorescent molecule calcein. As the quantity ofcalcein-AM that is delivered in the gut is dependent of the pumping rateof the pharynx, and hence of the activity of SERCA, the fluorescencemeasured in the gut of the formed calcein is a quantitative andqualitative measurement of the SERCA activity. It would be readilyapparent to one skilled in the art that other types of marker moleculeprecursor which are cleavable by an enzyme present in the gut of C.elegans to generate a detectable marker molecule could be used insteadof calcein-AM with equivalent effect.

[0035] In further embodiments, particularly suitable for use when thestarting worm strain exhibits reduced SERCA activity in the vulvamuscles, the up-regulation assay can be based on detection of changes inthe egg laying behaviour of the C. elegans or on detecting changes inthe amount of progeny produced by the C. elegans.

[0036] Defects associated with reduced SERCA activity in the vulvamuscles include defects in the production and laying of eggs and hence areduction in the number of progeny produced. Typically, worms withreduced SERCA expression in the vulva are not able to lay their eggs.The eggs thus hatch inside the mother, which then dies. These mothersare easy to recognize under the dissection microscope. As a consequenceof the egg laying defect, these worms produce less progeny, and hencethe culture as a whole grows much more slowly. Defects associated withreduced SERCA activity have also been observed in the gonad, includingthe sheath cells and the spermatheca. These defects also result inreduced egg formation and hence a reduced egg laying phenotype.

[0037] One convenient way in which the egg production and egg layingbehaviour of the worms can be monitored is by counting the number ofresultant offspring produced. A variety of different techniques can beused for this purpose. For example, the offspring can be measureddirectly using the growth rate assay and/or the movement assay describedbelow. Alternatively, specific antibodies and fluorescent antibodies canbe used to detect the offspring. Any specific antibody that onlyrecognizes eggs, or L1 or L2 or L3 or L4 stage worms, will onlyrecognize offspring, such a specific antibody that recognizes an antigenon the L1 surface has been described by Donkin and Politz, W13G10(2):71. Finally, the number of eggs or offspring in each well can becounted directly using a FANS device. The FANS device is a ‘wormdispenser apparatus’ having properties analogous to flow cytometers suchas fluorescence activated cell scanning and sorting devices (FACS) andis commercially available from Union Biometrica, Inc, Somerville, Mass.,USA. The FANS device, also designated a nematode flow meter, can be thenematode FACS analogue, described as fluorescence activated nematodescanning and sorting device (FANS). The FANS device enables themeasurement of nematode properties, such as size, optical density,fluorescence, and luminescence and the sorting of worms based on theseproperties.

[0038] In a still further embodiment, particularly suitable for use whenthe starting worm strain exhibits reduced SERCA activity in the analsphincter or the anal repressor, the up-regulation assay can be based ondetection of a change in the defecation behaviour of the C. elegans.

[0039] A reduction in the SERCA activity in the anal sphincter and/orthe anal repressor, for example following treatment with thapsigargin,results in worms which are constipated and also in worms with aprotruding rectum. Changes in the defecation rate of the worms cantherefore also serve as an indicator of SERCA activity.

[0040] Defecation rate can be measured using an assay similar to thatdescribed above for the measurement of pharynx pumping efficiency, butusing a marker molecule which is sensitive to pH. A suitable marker isthe fluorescent marker BCECF. This marker molecule can be loaded intothe C. elegans gut in the form of the precursor BCECF-AM which itself isnot fluorescent. If BCECF-AM is added to worms growing in liquid mediumthe worms will take up the compound which is then cleaved by theesterases present in the C. elegans gut to release BCECF. BCECFfluorescence is sensitive to pH and under the relatively low pHconditions in the gut of C. elegans (pH<6) the compound exhibits no orvery low fluorescence. As a result of the defecation process the BCECFis expelled into the medium which has a higher pH than the C. elegansgut and the BCECF is therefore fluorescent. The level of BCECFfluorescence in the medium (measured using a fluorimeter on settingsEx/Em=485/550) is therefore an indicator of the rate of defecation ofthe nematodes.

[0041] Defecation can also be measured using a method based on theluminescent features of the chelation of terbium by aspirin. The methodrequires two pre-loading steps, first the wells of a multi-well plateare pre-loaded with aspirin (prior to the addition of the nematodeworms) and second, bacteria or other nematode food source particles arepre-loaded with terbium using standard techniques known in the art. C.elegans are then placed in the wells pre-loaded with aspirin and are fedwith the bacteria pre-loaded with terbium.

[0042] The terbium present in the pre-loaded bacteria added to the wellswill result in a low level of background luminescence. When the bacteriaare eaten by the nematodes the bacterial contents will be digested butthe terbium will be defecated back into the medium. The free terbiumwill then be chelated by the aspirin which was pre-loaded into the wellsresulting in measurable luminescence. The luminescence thus observed istherefore an indicator of nematode defecation.

[0043] It has been observed that a reduction in SERCA activity, forexample using inhibition by thapsigargin or double stranded RNAinhibition, results in a reduction in the growth rate of a C. elegansculture. Growth rate of the culture as a whole is reduced because theworms produce fewer progeny and also because the few progeny that areproduced show poor/delayed growth. Cultures of worms which produce manyhealthy progeny grow faster than cultures of worms with few and/or sickprogeny. Hence measurement of the growth rate of a culture of C. elegansis in indication of the activity of SERCA in the individual worms of theculture.

[0044] Growth rate can be monitored by measuring the number of eggs orthe number offspring present in the culture, by measuring the totalfluorescence in the culture (this can be autoflourescence, orfluorescence caused by a transgene encoding a flourescent or luminescentprotein), but can also be measured using the movement screen describedbelow. Alternatively, the growth rate of a culture of C. elegans canalso be assayed by measuring the turbidity of the culture. In order toperform this ‘turbidity assay’ the worms are grown in liquid culture inthe presence of E. coli or other suitable bacterial food source. As theculture of worms grows the food source bacteria will be consumed. Thegreater the number of worms in the culture, the more food sourcebacteria will be digested. Hence, measurement of the turbidity oroptical density of the liquid culture will provide an indirectindication of the number of worms in the culture. By taking sequentialmeasurements over a period of time it is possible to monitor the growthrate of the whole C. elegans culture.

[0045] As an alternative to the above-described methods, the growth rateand amount of progeny can be measured on a plate. Slow growingnematodes, nematodes with vulva defects and nematodes with gonad defectswill produce less progeny within a certain time compared to nematodeswhich do not have these defects. Preferentially, the amount of offspringproduced is scored on day five and on day eight. In experiments wherethe amount of offspring is reduced very drastically due to severedefects in the vulva, gonad or growth rate reduction, the offspring canalso be scored at later time intervals.

[0046] In a still further embodiment, the up-regulation assay can beperformed by detecting changes in the movement behaviour of C. elegans.As is illustrated by the examples included herein, SERCA is widelyexpressed in the muscles of C. elegans, including the muscles of thebody wall. A reduction of SERCA activity in the body wall muscles givesrise to worms with movement defects. These strains can be used as thebasis of an assay in which the worms are contacted with a compound undertest and any changes in the movement behaviour of the worms areobserved. Compounds which cause the defective movement to revert towardswild-type movement behaviour are scored as compounds capable ofenhancing/up-regulating the activity of SERCA.

[0047] Changes in the movement behaviour of the worms can obviously bedetected by visual inspection, but as an alternative a number ofnon-visual approaches for analysing the movement behaviour of worms havebeen developed which can be performed in a multi-well plate format andare therefore suitable for use in high-throughput screening. Nematodeworms that are placed in liquid culture will move in such a way thatthey maintain a more or less even (or homogeneous) distributionthroughout the culture. Nematode worms that are defective in movementwill precipitate to the bottom in liquid culture. Due to thischaracteristic of nematode worms as result of their movement phenotype,it is possible to monitor and detect the difference between nematodeworms that move and nematodes that do not move. Advanced multi-wellplate readers are able to detect sub-regions of the wells of multi-wellplates. By using these plate readers it is possible to take measurementsin selected areas of the surface of the wells of the multi-well plates.If the area of measurement is centralized, so that only the middle ofthe well is measured, a difference in nematode autofluorescence(fluorescence which occurs in the absence of any external markermolecule) can be observed in the wells containing a liquid culture ofnematodes that move normally as compared to wells containing a liquidculture of nematodes that are defective for movement. For the wellscontaining the nematodes that move normally, a low level ofautofluorescence will be observed, whilst a high level ofautofluorescence can be observed in the wells that contain the nematodesthat are defective in movement.

[0048] In an adaptation of the movement assay, autofluorescencemeasurements can be taken in two areas of the surface of the well, onemeasurement in the centre of the well, and on measurement on the edge ofthe well. Comparing the two measurements gives analogous results as inthe case if only the centre of the well is measured but the additionalmeasurement of the edge of the well results in an extra control andsomewhat more distinct results.

[0049] As an alternative to the above-described embodiments of theup-regulation assay which are all based on the observation of changes inphenotypic and/or behavioural characteristics of the C. elegans as anindicator of SERCA activity, the inventors have developed a method ofanalysing SERCA activity in a given cell type or tissue which is basedupon the use of the marker molecule apoaequorin which is sensitive tochanges in intracellular Ca²⁺.

[0050] Aequorin is a calcium-sensitive bioluminescent protein from thejellyfish Aequorea victoria. Recombinant apoaequorin, which isluminescent in the presence of calcium but not in the absence ofcalcium, is most useful in determining intracellular calciumconcentrations and even calcium concentrations in sub-cellularcompartments. Expression vectors suitable for expressing recombinantapoaequorin and, in addition, vectors expressing apoaequorin proteinswhich are targeted to different sub-cellular compartments, for examplethe nucleus, the mitochondria or the endoplasmic reticulum are availablecommercially (see below).

[0051] As SERCA is a endoplasmic reticulum-localized calcium pump, anapoaequorin that is targeted to the endoplasmic reticulum (hereinafterreferred to as erAEQ) is particularly useful for developing assays forSERCA activity. Such apoaequorin is available from Molecular probes(Eugene, Oreg., USA). The vector erAEQ/pcDNAI (Molecular Probes)contains an Igγ2b heavy chain gene from mouse, an HA1 epitope and arecombinant apoaequorin in fusion. The mouse gene targets the aequorinto the endoplasmic reticulum, and the aequorin is mutated to make itless sensitive to calcium, as the concentrations of this ion arerelatively high in the endoplasmic reticulum. Although apoaequorin isthe calcium sensor of choice, it would be apparent to persons skilled inthe art that any other calcium sensor localized in the endoplasmicreticulum could be used with equivalent effect

[0052] Plasmid expression vectors which drive expression of theER-localized apoaequorin in C. elegans can be easily constructed bycloning nucleic acid encoding erAEQ downstream of a promoter capable ofdirecting gene expression in one or more tissues or cell types of C.elegans, such that the promoter and the erAEQ-encoding sequence areoperatively linked. As used herein the term “operatively linked” refersto a juxtaposition wherein the components described are in arelationship permitting them to function in their intended manner. In atypical cloning procedure, the apoaequorin gene in fusion with thesignals to locate the resulting protein to the endoplasmic reticulum wasisolated from erAEQ/pcDNAI by EcoRI digestion and cloned into pBlue2SK.The erAEQ was then isolated as an EcoRI/Acc65I fragment by partialdigestion and cloned in the vector pGK13 digested with the same enzymes.

[0053] Suitable promoters include the pharynx-specific promoter myo-2,the C. elegans SERCA promoter which directs expression in a wide rangeof muscle tissues and the body wall muscle-specific promoter myo-3. Thevectors can then be used to construct transgenic C. elegans according tothe standard protocols known to those of ordinary skill in the art.Expression of erAEQ allows for the determination of the calcium levelsin the endoplasmic reticulum of various C. elegans cells and tissues,using the protocols of the manufacturer of erAEQ, or minor modificationsthereof. Alterations in SERCA activity influence the concentration ofcalcium in the endoplasmic reticulum as SERCA functions as anendoplasmic reticulum calcium pump. Hence the apoaequorin luminescencemeasured in the assay is directly related to SERCA activity.

[0054] The basic ‘up-regulation assay’ methodology can also be adaptedto perform a genetic screen in order to identify C. elegans which carrya mutation having the effect of enhancing or up-regulating the activityof SERCA. Accordingly, the invention also provides a method ofidentifying C. elegans which carry a mutation having the effect ofenhancing or up-regulating the activity of a sarco/endoplasmic reticulumcalcium ATPase, which method comprises:

[0055] subjecting a population of C. elegans with wild-type SERCAactivity to random mutagenesis;

[0056] allowing the mutagenized C. elegans to grow for one or twogenerations;

[0057] treating the mutagenized C. elegans to reduce the activity of theSERCA ATPase in one or more cell types or tissues; and

[0058] scoring a phenotypic, biochemical or behavioural characteristicof the C. elegans as an indicator of SERCA ATPase activity in the C.elegans in the said one or more cell types or tissues.

[0059] This genetic screen differs from the ‘up-regulation’ assay usedto identify compounds in that the C. elegans are subjected to a randommutagenesis step before they are treated to reduce the activity of theSERCA ATPase. The random mutagenesis step can be performed using any ofthe techniques known in the art. EMS and UV-TMP mutagenesis, both ofwhich are well known in the art (see Methods in Cell biology Vol. 48,1995, ed. by Epstein and Shakes, Academic press) are preferred. Aftermutagenesis the worms are grown for one or two generations before theyare treated to reduce the activity of SERCA. After one generation, theworms are heterozygous for any mutation, after two generations they maybe homozygous or heterozygous for any mutation. Therefore growth for onegeneration leads to isolation of dominantly acting suppressors, growthfor two generations yields both recessively and dominantly actingsuppressors.

[0060] The step of treating the C. elegans to reduce the activity of theSERCA ATPase preferably comprises either treating the worms with achemical inhibitor of SERCA, for example thapsigargin, or specificallydown-regulating the expression of SERCA using antisense ordouble-stranded RNA inhibition.

[0061] When thapsigargin is added to worms in plate or liquid culturefew progeny are produced and these don't grow as well as wild-typeworms. To perform a genetic screen based on thapsigargin inhibitionwild-type worms are first subjected to standard mutagenesis protocols(using EMS or UV/TMP or any other mutagen). F1 or F2 progeny of themutagenized worms are distributed individually to standard growth mediumwith bacteria, to which 10 to 50 mM thapsigargin is added. After 4-8days the cultures are inspected for growth of progeny, either by eye orusing the ‘turbidity assay’, as described above. Wild-type C. eleganswith an integrated transgenic array causing general expression of areporter protein such as GFP can also be used. In this case, culturesare inspected for growth of progeny either by eye or by detectingexpression of the reporter protein.

[0062] Thapsigargin causes a short term pharynx pumping defect. Hence,the genetic screen can also be performed by measuring changes in thepharynx pumping efficiency. Wild-type worms are mutagenized and grown onsolid media according to standard techniques known in the art. Adultsare washed off the plates and put in buffer with calcein-AM andthapsigargin (an assay buffer of 40 mM NaCl, 6 mM KCl, 1 mM CaCl₂, 1 mMMgCl₂ can be used for this purpose). After two hours the worms areviewed under a fluorescence microscope and individual worms that showfar brighter gut fluorescence than the other worms are selected, placedindividually onto fresh plates and grown for an additional generation.Calcein-AM uptake in the presence of thapsigargin is then re-checked.

[0063] Inhibition of SERCA by antisense or double stranded-RNAinhibition will result in the same phenotypes as described above for theup-regulation assay and hence the same screens can be used to select formutants that enhance or up-regulate SERCA activity. The precise natureof the screen used depends on the tissue in which the antisense ordouble stranded SERCA RNA is expressed.

[0064] An analogous genetic screen can also be performed using areduction-of-function mutant C. elegans strain which exhibits reduced C.elegans activity in one or more cell types or tissues. Accordingly, in afurther aspect the invention provides a method of identifying C. eleganswhich carry a mutation having the effect of enhancing or up-regulatingthe activity of a sarco/endoplasmic reticulum calcium ATPase, whichmethod comprises the steps of:

[0065] subjecting a population of mutant C. elegans which exhibitreduced SERCA activity in one or more cell types or tissues to randommutagenesis;

[0066] allowing the mutagenized C. elegans to grow for one or twogenerations; and

[0067] scoring a phenotypic, biochemical or behavioural characteristicof the C. elegans as an indicator of SERCA ATPase activity in the C.elegans in the said one or more cell types or tissues.

[0068] A suitable reduction-of-function mutant strain can be isolated asdescribed above.

[0069] The basis of the above-described genetic screens is to screen formutations that have the effect of enhancing or up-regulating SERCAactivity and thus suppress the inhibitory effect of thapsigargintreatment, antisense or double stranded RNA inhibition of SERCAexpression or a reduction-of-function mutation. Mutations likely to beidentified using the method of the invention include mutations in genesinvolved in transcription and/or translation of SERCA, mutations thatinfluence Ca²⁺ cycling between the ER and cytoplasm, mutations thatinfluence Ca²⁺ buffering and mutations that influence the activity ofCa²⁺ binding proteins. Once a mutant worm has been identified using agenetic screen it is a matter of routine to identify the mutated geneusing techniques commonly used in the art.

[0070] In summary, the up-regulation assay which may be used to identifycompounds which enhance the activity and/or expression of SERCA is basedon the use of C. elegans worms in which the activity or expression ofthe C. elegans SERCA protein is reduced. This may be achieved in atleast three different ways. First, mutants can be selected that showreduced SERCA activity. Second, wild-type, mutant, or transgenic C.elegans strains can be treated with compounds that inhibit SERCAactivity, such as thapsigargin. Third, RNAi technology can be applied towild-type, mutant or transgenic C. elegans to reduce the SERCA activity.In each case, screening can be performed to select for compounds thatenhance SERCA activity. Such screens may be based on the pharynx pumpingrate, egg laying or movement. In a particular example of theup-regulation assay, wild-type, mutant or transgenic strains can be madetransgenic for apoaequorin or another calcium marker. These markers maybe expressed in the various tissues, such as the pharynx, the body wallmuscles, the oviduct, vulva-muscles etc, for which specific promotersare known in the art. Apoaequorin may also be expressed more generallyin C. elegans, for instance under the control of the SERCA promoter. Theapoaequorin may further be fused to a specific signal peptidetranslocating the apoaequorin to the endoplasmic reticulum. Selectingcompounds that enhance the activity or the expression of SERCA willenhance calcium uptake, and hence increase the bio-luminescence of theapoaequorin located in the lumen of the endoplasmic or sarcoplasmicreticulum.

[0071] In a second aspect the invention provides a method of identifyingcompounds which modulate the interaction between a sarco/endoplasmicreticulum calcium ATPase and phospholamban, which method comprises:

[0072] exposing transgenic C. elegans which contains a first transgenecomprising nucleic acid encoding a vertebrate PLB protein and whichexpresses a SERCA protein to a compound under test; and

[0073] detecting a phenotypic, biochemical or behavioural change in thetransgenic C. elegans indicating an increase in the activity of theSERCA protein.

[0074] The vertebrate phospholamban (PLB) protein used in this secondmethod of the invention, hereinafter referred to as the ‘interactionassay’ can be any vertebrate PLB protein. Most preferred are pig PLB(GenBank P07473) or human PLB (GenBank P26678) or a humanized pig PLB(see below). Mutant PLB proteins which exhibit stronger or weakerinhibition of SERCA relative to the wild-type protein may also be used.

[0075] The SERCA protein expressed by the C. elegans may be a C. elegansSERCA protein, a vertebrate SERCA protein, a fusion between a vertebrateSERCA protein and C. elegans SERCA protein or a mutant SERCA protein,for example a mutant which exhibits greater sensitivity to PLB.

[0076] The vertebrate SERCA protein can be any vertebrate SERCA isoform.Preferred isoforms are pig SERCA2a (GenBank P11606), human SERCA1a(GenBank AAB 53113), human SERCA1b (GenBank AAB 53112), human SERCA2a(GenBank P16614) and human SERCA2b (GenBank P16615). Human and pigSERCA2a are most preferred.

[0077] Various types of fusion proteins between C. elegans SERCA andvertebrate SERCA proteins which may be used in the method of theinvention are described in the accompanying Examples. For example, thefusion might comprise the N-terminal part of C. elegans SERCA and theC-terminal part of a vertebrate SERCA.

[0078] It is essential that a ‘functional’ combination of SERCA and PLBis chosen i.e. that the SERCA protein and the PLB protein are able tointeract with each other such that the activity of SERCA can beinhibited by the PLB, mimicking the regulatory interaction occurring invertebrates.

[0079] In the context of this application the term “transgene” refers toa DNA construct comprising a promoter operatively linked to aprotein-encoding DNA fragment. The construct may contain additional DNAsequences in addition to those specified above. The transgene may, forexample, form part of a plasmid vector. By the term “operatively linked”it is to be understood that the promoter is positioned to drivetranscription of the protein-encoding DNA fragment.

[0080] Methods of preparing transgenic C. elegans, including wormscarrying multiple transgenes, are well known in the art and areparticularly described by Craig Mello and Andrew Fire, Methods in CellBiology, Vol 48, Ed. H. F. Epsein and D. C. Shakes, Academic Press,pages 452-480. A typical approach involves the construction of aplasmid-based expression vector in which a protein-encoding DNA ofinterest is cloned downstream of a promoter having the appropriatetissue or cell-type specificity. The plasmid vector is then introducedinto C. elegans of the appropriate genetic background, for example usingmicroinjection. In order to facilitate the selection of transgenic C.elegans a second plasmid carrying a selectable marker may be co-injectedwith the experimental plasmid.

[0081] The plasmid vector is maintained in cells of the transgenic C.elegans in the form of an extrachromosomal array. Although plasmidvectors are relatively stable as extrachromosomal arrays they canalternatively be stably integrated into the C. elegans genome usingstandard technology, for example, using gamma ray-induced integration ofextrachromosomal arrays (methods in Cell Biology, Vol 48 page 425-480).

[0082] The DNA fragment encoding the SERCA protein or the PLB proteinmay be a fragment of genomic DNA or cDNA. Preferably the DNA encodingthe vertebrate SERCA protein is operatively linked to the promoterregion of a SERCA gene. Most preferably the promoter region of the C.elegans SERCA gene is used. The term ‘promoter region’ as used hereinrefers to a fragment of the upstream region of a given gene which iscapable of directing a pattern of gene expression substantiallyidentical to the natural pattern of expression of the given gene.

[0083] Provided that a functional combination is chosen, wherever theSERCA protein and the vertebrate PLB are co-expressed the two proteinswill interact such that PLB inhibits the activity of SERCA. The aim ofthe interaction assay is to identify compounds which directly orindirectly disrupt the SERCA/PLB interaction, leading to an increase inSERCA activity. The increase in SERCA activity is monitored indirectly,by detecting phenotypic, biochemical or behavioural changes in the C.elegans which are indicative of an increase in SERCA activity.Advantageously, the nucleic acid encoding PLB is operatively linked to atissue-specific promoter. With the use of a promoter of appropriatespecificity, the vertebrate PLB can be expressed in all the cells of C.elegans , in a given type of tissue (i.e. all muscles), in a singleorgan or tissue (for example, the pharynx or the vulva), in a subset ofcell types, in a single cell type or even in a single cell.

[0084] By restricting the expression of PLB to certain tissues it ispossible to specifically down-regulate SERCA activity in these tissuesand thus to influence the phenotype of the resultant transgenic worms.For example, when PLB is expressed in the pharynx, the resultantinhibition of SERCA activity in the pharynx results in a reduction inthe rate of pharynx pumping. When PLB is expressed in the vulva muscles,the resultant inhibition of SERCA activity in the vulva results in anegg laying defect.

[0085] Although the interaction assay may be performed using functionalcombinations of C. elegans SERCA (especially mutant versions thereof, asdiscussed below) and vertebrate PLB, it is preferred to use functionalcombinations of vertebrate SERCA and vertebrate PLB. In order to ensurethat the interaction assay can be used to identify compounds whichspecifically modulate the vertebrate SERCA/vertebrate PLB interaction itis preferred to use a transgenic strain which has been modified suchthat expression of the endogenous C. elegans SERCA protein is abolishedor substantially reduced down to background levels. This may be achievedby introducing the transgenes encoding the vertebrate SERCA and PLB intoa mutant strain having a knock-out or loss-of-function mutation in thechromosomal C. elegans SERCA gene (e.g. strain ok190 described in theaccompanying Examples). A protocol for isolating a suitable knock-outmutant strain is given in the examples included herein. In a variationof this approach, expression of the endogenous C. elegans SERCA gene maybe abolished/reduced using RNAi technology, as described hereinbefore.In this case, the genetic background of the transgenic C. elegans may bewild-type.

[0086] In a further embodiment, a vertebrate-specific interaction assaymay be achieved by using transgenic C. elegans expressing a mutantversion of the vertebrate SERCA protein which is resistant to a chemicalinhibitor of SERCA activity, such as thapsigargin. The mutationPhe259Val renders C. elegans SERCA resistant to inhibition withthapsigargin. Equivalent mutations may be introduced into transgenesencoding the vertebrate SERCA proteins using standard site-directedmutagenesis. Applying the SERCA inhibitor, e.g. thapsigargin, totransgenic C. elegans which express a resistant mutant vertebrate SERCAand a vertebrate PLB will result in inhibition of the endogenous C.elegans SERCA only. Thus, if the inhibitor is added to the interactionassay in addition to the test compound, the screen will be specific forthe interaction between the vertebrate SERCA and the vertebrate PLB.

[0087] A particular variant of the interaction assay uses a mutantversion of the C. elegans SERCA protein which is more sensitive tovertebrate PLB proteins, such as, for example, a C. elegans SERCAcontaining the KDDKPV (SEQ ID NO:39) insertion. As illustrated in theaccompanying Example 9, introduction of the amino acid sequence KDDKPV(SEQ ID NO:39) into the C. elegans SERCA protein results in a moreefficient interaction between the mutant SERCA and vertebrate PLB.Therefore, double transgenic C. elegans strains containing a firsttransgene encoding a vertebrate PLB protein and a second transgeneencoding a C. elegans SERCA KDDKPV (SEQ ID NO:39) insertion mutant maybe used in the interaction assay.

[0088] In order to provide specificity for the mutant SERCA/PLBinteraction, it is preferred that the double transgenic is also modifiedsuch that expression of the endogenous C. elegans SERCA gene isabolished or substantially reduced. As described above, this may beachieved by using a mutant C. elegans genetic background having aknock-out or loss-of-function mutation in the chromosomal SERCA gene orby using RNAi technology to inhibit SERCA expression. Alternatively, itis possible to engineer the mutant SERCA so that in addition to theKDDKPV (SEQ ID NO:39) insertion it also carries a further mutation whichrenders it resistant to a SERCA inhibitor other than PLB, e.g. thethapsigargin resistance mutation Phe259Val. Addition of the SERCAinhibitor, e.g. thapsigargin, to the assay will result in specificinhibition of the endogenous C. elegans SERCA protein but not theresistant mutant.

[0089] As with the ‘up-regulation assay’ described above, the step of“detecting a phenotypic, biochemical or behavioural change in thetransgenic C. elegans indicating an increase in the activity of SERCA”can be performed in several different ways.

[0090] In one embodiment, particularly suitable for use when thetransgenic C. elegans expresses PLB in the pharynx, the method isperformed by detecting changes in the pharynx pumping efficiency. Therate of pharynx pumping can be measured using a marker moleculeprecursor such as calcein-AM, as described above for the up-regulationassay.

[0091] In still further embodiments, particularly suitable for use whenthe transgenic C. elegans expresses PLB in the vulva, the method can beperformed by detecting changes in the egg laying behaviour of the C.elegans or by detecting changes in the number of progeny produced by theC. elegans. The number of progeny produced by the C. elegans can, asdescribed above in connection with the up-regulation assay, be directlycounted or can be measured indirectly using a growth assay or aturbidity assay.

[0092] In a still further embodiment, again particularly suitable foruse when the transgenic C. elegans expresses PLB in the pharynx, SERCAactivity in cells of the C. elegans pharynx can be monitored usingapoaequorin luminescence. To achieve this the C. elegans are transfectedwith a third transgene which comprises nucleic acid encoding anapoaequorin protein, preferably ER-targeted apoaequorin, operativelylinked to promoter capable of directing gene expression in the C.elegans pharynx. The construction of suitable expression vectorscomprising such a transgene has been described hereinbefore.

[0093] In summary, the basic SERCA-PLB interaction screen to select forcompounds that inhibit the interaction between SERCA and PLB is based onthe construction of transgenic C. elegans expressing PLB. The PLB may beof any vertebrate origin, such as human or pig. The PLB may be expressedubiquitously or in specific tissues, such as the pharynx, the body wallmuscles, the oviduct, vulva muscles etc, for which specific promotersare known in the art. Preferred configurations of the interaction assayare summarised below, however, this is not intended to be limiting tothe scope of the invention:

[0094] Double transgenic C. elegans, first transgene encoding avertebrate PLB, second transgene encoding a vertebrate SERCA; expressionof endogenous C. elegans SERCA abolished/reduced by mutation of theSERCA gene in the genetic background or by using RNAi on wild-typegenetic background,

[0095] Double transgenic C. elegans , first transgene encoding avertebrate PLB, second transgene encoding a fusion between C. elegansSERCA and a vertebrate SERCA; expression of endogenous C. elegans SERCAabolished/reduced by mutation of the SERCA gene in the geneticbackground or by using RNAi on wild-type genetic background,

[0096] Double transgenic C. elegans , first transgene encoding avertebrate PLB, second transgene encoding a mutant vertebrate SERCAwhich is resistant to a SERCA inhibitor other than PLB, e.g.thapsigargin; wild-type genetic background; inhibitor is added to theassay in addition to the compound under test to specifically inhibitendogenous C. elegans SERCA expression,

[0097] Double transgenic C. elegans , first transgene encoding avertebrate PLB, second transgene encoding a mutant C. elegans SERCAwhich is more sensitive to inhibition by vertebrate PLB (e.g. KDDKPV(SEQ ID NO:39) insertion); expression of endogenous C. elegans SERCAabolished/reduced by mutation of the SERCA gene in the geneticbackground or by using RNAi on wild-type genetic background,

[0098] Double transgenic C. elegans, first transgene encoding avertebrate PLB, second transgene encoding a double mutant C. elegansSERCA which is (i) more sensitive to inhibition by vertebrate PLB (e.g.KDDKPV (SEQ ID NO:39) insertion) and (ii) resistant to inhibition by aSERCA inhibitor such as thapsigargin (e.g. Phe259Val); wild-type geneticbackground; inhibitor is added to the assay in addition to the compoundunder test to specifically inhibit endogenous C. elegans SERCAexpression.

[0099] In a third aspect the invention provides a method of identifyingcompounds capable of down-regulating the activity of a sarco/endoplasmicreticulum calcium ATPase, which method comprises:

[0100] exposing transgenic C. elegans containing a transgene comprisingnucleic acid encoding a SERCA protein operatively linked to a promotercapable of directing gene expression to a sample of the compound undertest; and

[0101] detecting a phenotypic, biochemical or behavioural change in thetransgenic C. elegans indicating a decrease in the activity of the SERCAprotein.

[0102] The SERCA protein used in this third aspect of the invention,hereinafter referred to as the ‘down-regulation assay’ can be any SERCAisoform from any species. Preferably the SERCA protein is C. elegansSERCA, pig SERCA2a, or a human SERCA isoform, most preferably humanSERCA 2A.

[0103] Preferably the nucleic acid encoding the SERCA protein isoperatively linked to a tissue-specific promoter. Most preferably, thetissue-specific promoter is the C. elegans myo-2 promoter which directstissue-specific expression in the pharynx.

[0104] In a preferred embodiment the transgenic C. elegans furthercontain a second transgene comprising nucleic acid encoding a reporterprotein operatively linked to a promoter which is capable of directinggene expression in one or more cell types or tissues of C. elegans. Thereporter protein is preferably an autonomous fluorescent protein, forexample, a green fluorescent protein or a blue fluorescent protein or aluminescent protein.

[0105] Transgenic C. elegans over-expressing SERCA are generallyobserved to be starved and show delayed growth. Compounds which reduceor down-regulate the activity of SERCA will cause a reversion orreduction of this phenotype towards a wild-type phenotype. Accordingly,these worms can be used as a basis of a screen to identify compoundscapable of reducing or down-regulating the activity of SERCA, bybringing the worms into contact with the compound under test and thendetecting a reversion of the over-expression phenotype reflecting adecrease in the activity of the SERCA transgene.

[0106] The step of “detecting a phenotypic, biochemical or behaviouralchange in the transgenic C. elegans indicating a decrease in theactivity if the SERCA protein” can be performed in several differentways. As mentioned above, transgenic C. elegans which overexpress theSERCA protein exhibit delayed growth. Accordingly, it is possible tolook for a reversion of the overexpression phenotype by comparing thegrowth rate of the transgenic C. elegans in the presence and the absenceof the compound under test. Compounds which increase the growth rate ofthe C. elegans culture are scored as compounds which are capable ofreducing or down-regulating SERCA activity. Any of the growth assaymethods described in connection with the ‘up-regulation’ assay could beused for this purpose.

[0107] Transgenic C. elegans which overexpress SERCA also exhibitaltered egg laying behaviour and reduced pharynx pumping. Hence, thedown-regulation assay can also be performed by detecting changes in theegg laying behaviour or the pharynx pumping efficiency, as describedpreviously.

[0108] In summary, the basic down-regulation assay consists ofintroducing extra SERCA into C. elegans and screening for a compoundthat inhibits SERCA activity. The SERCA introduced into C. elegans maybe C. elegans SERCA or a SERCA of any vertebrate origin, such as humanor pig. The SERCA protein may be expressed ubiquitously or in specifictissues such as the pharynx, the body wall muscles, the oviduct, thevulva muscles etc, for which appropriate tissue or cell type-specificpromoters are known in the art.

[0109] The above-described methodology for the down-regulation assay canbe adapted to perform a genetic screen to identify C. elegans carrying amutation having the effect of reducing or down-regulating SERCAactivity. Thus, in a further aspect the invention provides a method ofidentifying C. elegans which carry a mutation having the effect ofreducing or down-regulating the activity of a sarco/endoplasmicreticulum calcium ATPase, which method comprises the steps of:

[0110] providing a transgenic C. elegans strain containing a firsttransgene comprising nucleic acid encoding a SERCA protein operativelylinked to a promoter capable of directing gene expression in one or morecell types or tissues of C. elegans;

[0111] subjecting a population of the said C. elegans strain to randommutagenesis;

[0112] allowing the mutagenized C. elegans to grow for one or moregenerations; and

[0113] scoring a phenotypic, biochemical or behavioural characteristicof the C. elegans as an indicator of SERCA ATPase activity in the C.elegans in the said one or more cell types or tissues.

[0114] The genetic screen is preferably carried out using transgenic C.elegans containing an integrated transgene harboring 20-50 ng/μl pGK7(containing the C. elegans genomic SERCA gene, including the promoterregion, see examples given below) and a general GFP expressingconstruct. These worms are starved and show general growth delay. Thesame results are obtained using a vertebrate SERCA, such as the human orpig SERCA.

[0115] Alternatively, the screen can be performed using transgenicnematodes containing an integrated transgene harboring the genomic C.elegans SERCA gene operatively linked to the myo-2 promoter, and ageneral GFP expressing construct. These worms are also starved and showgrowth delay.

[0116] The worms are grown and subjected to random mutagenesis accordingto standard techniques known in the art. The mutagenized worms then aredistributed individually to standard growth medium with supplementedwith food source bacteria. After 4-8 days the cultures are inspected forgrowth of progeny, either by eye, by using any of the growth assaytechniques mentioned previously in connection with the up-regulationassay, using the turbidity assay or by counting the numbers of progenyproduced.

[0117] The basis of these genetic screens is that mutations having theeffect of reducing or down-regulating SERCA activity will suppress theeffect of SERCA over-expression. Mutations identified using this screenmay include mutations in genes involved in transcription and/ortranslation of SERCA, mutations that influence Ca²⁺ cycling between theER and the cytoplasm, mutations that influence Ca²⁺ buffering andmutations that influence the activity of Ca²⁺ binding proteins.

[0118] In the field of human pharmaceuticals, compounds identified asmodulators of SERCA activity using the screening methods of theinvention may be useful leads in the development of pharmaceuticals forthe treatment of the wide range of diseases with which the SERCA geneshave been associated, such as cardiac hypertrophy, heart failure,hypertension, NIDDM, Darier-White disease, Brody's disease.

[0119] Outside the pharmaceutical field, compounds identified asmodulators of SERCA activity may find important applications aspesticides, particularly insecticides, herbicides or nematocides.Maintaining high calcium concentrations in the ER is important for theproper synthesis of protein, including translation, folding,glycosylation, processing and transport. Treatment of living organismswith chemicals that inhibit the activity of SERCA will hence have anegative effect on the welfare of these organisms. As such, SERCAinhibitors are potential pesticides or can be considered as basiccompounds for the development of pesticides such as herbicides,insecticides and nematocides. It has been shown that SERCA function isessential in the intracellular trafficking of the Notch receptor indrosophila (Periz et al., 1999 EMBO J; 5983-5993). This studies andothers indicate that SERCA is an interesting target for pesticidalintervention. Accordingly, the screening methods described herein couldbe applied to screen for pesticides.

[0120] The invention will be further understood with reference to thefollowing experimental Examples together with the accompanying Figuresin which:

[0121]FIG. 1 shows a dose-response curve for thapsigargin produced usinga liquid culture assay.

[0122]FIG. 2 shows a dose-response curve for thapsigargin produced usinga plate assay.

[0123]FIG. 3 illustrates the growth of C. elegans strain UG530 (strainharboring plasmid pGK28) on different concentrations of thapsigargin.The stage of the progeny was determined 5 days after adults were put onthe plates. Since the mothers carry the pGK28 containing plasmid on anextrachromosomal transgene, part of the progeny inherited it and part ofthe progeny did not. These were differentiated based on a GFP markeralso present on this transgene.

[0124]FIG. 4 illustrates the nucleotide sequence of the genomic fragmentof C. elegans SERCA bounded by primers SERCA P4 and SERCA P8. Exon IVand exon V are shown in capitals, intron IV in lower case. The fragmentdeleted in ok190 is underlined.

[0125] All Molecular biology work was performed as described by Sambrooket al. Molecular cloning, A Laboratory Manual, Cold Spring HarborLaboratory Press, or using minor modifications of the methods describedtherein.

[0126] All manipulations of C. elegans worms were performed usingtechniques described in Methods in Cell Biology, vol 84; Caenorhabditiselegans: modern biological analysis of an organism, ed. Epstein andShakes, academic press, 1995, or using minor modifications of themethods described therein.

[0127] Transgenic C. elegans strains were constructed by injection ofplasmid DNA into worms using standard techniques known in the art (seeMethods in Cell Biology, vol 84 as mentioned above).

EXAMPLE 1

[0128] Inhibition of Expression of C. elegans SERCA Using RNAi.

[0129] 732 bp EcoRI-HindIII fragment from C. elegans SERCA exon 5 (SEQID NO: 1) was PCR amplified and cloned into the vector pGEM3 (PROMEGAcorporation, Madison, Wis., USA). RNA was in vitro transcribed from bothstrands using standard procedures. The generated double stranded RNA wasinjected into C. elegans (see Fire at al., 1998, Nature 391:806-811).This resulted in the following phenotypes: 50% of the progeny of theinjected animals were embryonic lethal, while the other 50% were earlylarval lethal. This indicates that SERCA function is vital for C.elegans. In conclusion, inhibition of the expression of SERCA in alltissues results in embryonic or early larval lethality of the nematode.

[0130] Inhibition of SERCA Using RNAi Feeding Technology

[0131] Although injection of SERCA dsRNA results in a clear phenotype,useful in the development of assays to select for compounds that alterthe SERCA activity, or that alter the activity of partners in the SERCApathway, or that alter the activity proteins involved in calciummetabolism, a more stable RNAi phenotype would be more efficient.Improved RNAi methods which lead to more stable RNAi phenotypes existand are described, for example in International patent application No.WO 00/01846. More particularly, an RNAi technology has been developedand tested in which dsRNA can be delivered by feeding the nematode dsRNAor by feeding nematodes with DNA.

[0132] pGN4 was constructed by cloning the HindIII-EcoRI fragment ofSERCA cloned in vector pGN1 using these same restriction sites. This isthe same fragment as was used for in vitro transcription and dsRNAinjection, described above.

[0133] HT115(DE3) bacteria (Fire A, Carnegie Institution, Baltimore,Md.) were transfected with pGN4 (and controls with pGN1) and seeded onplates containing IPTG and ampicillin resulting in a high expression ofdsRNA by the bacteria. N2 and nuc-1 (e1392) adult nematodes were put onthese plates and allowed to lay eggs and the progeny was followed overtime. The progeny mostly looked healthy during the larval stages, butthe adults (and some of the L4) had a starved appearance (nuc-1 morepronounced then N2). Pumping was irregular and slower then normal, andthe growth rate was somewhat reduced. This example indicates that astable RNAi phenotype useful in assay development and compound screeningcan be developed using feeding. As described in co-pending applicationNo. WO 00/01846, other possibilities and variants can be used to createa C. elegans SERCA RNAi phenotype. The use of RNAi technology allows thedevelopment of screens for compounds that alter SERCA activity or thatalter the SERCA pathway, without the construction of a C. elegans SERCAmutant. E. coli HT115 has the following characteristics which make it auseful host cell for high level expression of dsRNA: HT115 (DE3): F-mcrAmcrb IN(rrnD-rrnE) 1 γ-rnc14::tr10 (DE3 lysogen: lacUV5 promoter-T7polymerase); host for IPTG inducible T7 polymerase expression;RnaseIII-. Other host strains suitable for expression of dsRNA could beused with equivalent effect.

EXAMPLE 2

[0134] Overexpression of C. elegans SERCA.

[0135] A 11207 bp SpeI-MluI fragment from the cosmid K11D9 (SEQ ID NO:2)was cloned into the vector pUC18 (Messing, J., 1998, Methods in Enzymol.101: 20), resulting in the plasmid pGK7. This genomic fragment containsthe complete SERCA gene with 5631 bp upstream sequences, the completecoding region and 1088 bp downstream sequences. Transfection of C.elegans with this vector using standard technology resulted in variousresults. Transfection with high concentrations of DNA (80-200 ng/μl)induced embryonic lethality. At lower concentrations of DNA (20-50ng/μl) worms were generally sick; also they were constipated, showed astarved appearance, and had pharynx pumping defects. These experimentsindicate the importance of fine-tuning the expression level of SERCA inthe nematode C. elegans. High levels of overexpression of SERCA islethal, as is inhibition of expression. Furthermore, intermediate levelsof overexpression of SERCA results in defects all over the worm,affecting almost all vital functions.

EXAMPLE 3

[0136] Expression Pattern of SERCA in C. elegans.

[0137] A 5026 bp fragment of the upstream region of the C. elegans SERCAgene, starting 5026 bp upstream of the translation initiation codon andcontinuing up to and including the A of the ATG initiation codon (SEQ IDNO:3), was cloned into the vector pPD95.79 (described in Fire et al.(1990) Gene, 93: 189-198)in fusion with a GFP fluorescent protein,resulting in vector pGK10. The cloned fragment can be considered as thepromoter region of the C. elegans SERCA. The vector was injected into C.elegans, using standard methodology well known to persons skilled in theart, and the expression of the GFP was monitored applying standardfluorescent techniques. GFP expression was observed all over the earlyembryo of the worm, although expression was faint in some tissues. In alater stage of development, from mid-embryo stage, through larval stageto adult stage, strong GFP expression could be observed in all muscletissue, including the pharyngeal muscles, the body wall muscles, theanal depressor and the anal sphincter. In adults staining was seen inthe vulva muscles, the uterine muscles, the spermatecae and the proximalmyoepithelial sheath cells of the gonad.

[0138] A construct containing a smaller promoter fragment, including Aof the initiating ATG codon and extending 2915 bp upstream (SEQ IDNO:4), fused to a GFP gene was generated by a PstI deletion of theplasmid pGK10. This plasmid was designated pGK13. Transfection of thenematode with pGK13 resulted in the same pattern of GFP expression aswas observed with pGK10.

[0139] Finally, a third construct was made containing a 6612 bp fragmentof the C. elegans SERCA gene in the plasmid pPD95.75 (described in Fireet al. (1990) Gene, 93: 189-198). The resultant plasmid was designatedpGK12. This 6612 bp fragment contains 5637 bp of upstream sequences anends in exon 4 of the C. elegans SERCA gene (SEQ ID NO:5). The fragmentwas cloned as a SalI-BglII fragment isolated from pGK7, and cloned infusion to GFP. This fragment contains two transmembrane domains ofSERCA. Transfection of C. elegans with this construct resulted in thesame pattern of GFP expression as was observed with pGK10 and pGK13,i.e. GFP expression could be localized to the muscle tissues of C.elegans. Detailed analysis of the expression pattern in the musclesshowed clearly that the GFP protein was localized to the endoplasmicreticulum and the dense bodies.

[0140] These expression studies clearly demonstrate that the SERCAprotein of C. elegans is expressed in all muscle tissue, and that it islocalized in the endoplasmic reticulum, indicating that the C. elegansSERCA probably has analogous function to the vertebrate SERCAs.

[0141] In addition to pGK10, pGK12 and pGK13, several further constructshave been used to analyse the pattern of SERCA expression in C. elegans.These are summarised as follows:

[0142] pGK26 contains GFP inserted directly after the CDS of C. elegansSERCA isoform A using overlap PCR, also containing the SERCA downstreamregion.

[0143] pGK27 contains GFP inserted directly after the CDS of the C.elegans SERCA isoform B using overlap PCR, also containing the SERCAdownstream region.

[0144] pGK26 was constructed by the following strategy: Three separatePCR reactions were done to yield three PCR fragments that are joined inconsequent overlap PCR. The first fragment is made with theoligonucleotides oGK25 and oGK26 and contains the region upstream ofwhere GFP is inserted. The primer oGK26 is an overlap primer andcontains the last 21 nt of SERCA until but not including the stop codonfollowed by the first 15 nt of GFP. The second fragment contains thecomplete ORF of GFP including the stop codon. The third fragment is madewith oGK27 and oGK28 and contains the region downstream of where GFP isinserted. The primer oGK27 is an overlap primer and contains the last 15nt of GFP including the stop codon and the first 22 nt of the 3′ UTR.The end result after overlap PCR is a “recombination” of these threefragments in which GFP is inserted exactly after and in-frame with theSERCA coding region such that the fragment encodes a SERCA::GFP fusionprotein. This PCR fragment is cloned into pGK7 to replace the normalC-terminus of the gene using unique restriction sites in the SERCAcoding region and 3′ UTR (ApaI in the first fragment and PacI in thethird fragment).

[0145] pGK27 was constructed the same way, using primers oGK21 and oGK22instead of oGK25 and oGK26, and primers oGK23 and oGK24 instead ofprimers oGK27 and oGK28.

[0146] Sequence of primers:

[0147] oGK21: TGGACTCATCTCTGGATGGCTC (SEQ ID NO:17)

[0148] oGK22: CTTCTCCTTTACTCATCAATTCGTTATGTAACTTGTCGG (SEQ ID NO:18)

[0149] oGK23: GAACTATACAAATAGTTGAAGTTCTTCTAACCCCC (SEQ ID NO:19)

[0150] oGK24: GCGTTTATCCTTGATTGGAGCTTC (SEQ ID NO:20)

[0151] oGK25: GAATGGATCGCCGTGTTGAAG (SEQ ID NO:21)

[0152] oGK26: TTCTCCTTTACTCATGTCGCGTTTATCCTTGATTGG (SEQ ID NO:22)

[0153] oGK27: GAACTATACAAATAGAAATGACAGTGCTCCCTCAATC (SEQ ID NO:23)

[0154] oGK28: GTGGGATCCTGGTTTGTTCTGAG (SEQ ID NO:24)

[0155] When the various constructs were injected into wild-type C.elegans the following expression patterns were observed:

[0156] Expression was observed in all muscle types, such as the bodywall muscle, the pharynx, the vulva muscle, the uterine muscles etc, butexpression was also observed in the anal depressor, the gut, the gonadsheath cells etc. (see Table 1). This is not unexpected, due to theimportance of SERCA in the calcium metabolism of C. elegans , as hasalso been observed in other organisms. Moreover the various constructsgive different expression patterns, indicating complex regulation ofSERCA expression as suggested.

[0157] The expression patterns of the constructs, and hence of theendogenous SERCA, indicate that various assays can be developed. Theseinclude assays based on body wall muscle function and hence on movement,assays on pharyngeal function and hence on the pumping rate, assays onvulva muscle function and hence on egg laying, assays on anal repressorfunction and hence on defecation, assays on the gonad sheath cell,uterine muscle and uterine sheath cell function and hence on egg laying.TABLE 1 expression patterns for SERCA constructs in wild-type C.elegans. pGK10 pGK26 pGK27 body wall/head muscle Yes Yes Yes ER No YesYes dense bodies No Yes Yes muscle arms Yes No No pharynx Yes Yes Yes TBYes Yes Yes isthmus Yes Yes Yes metacorpus No No No procorpus No No Novulva muscles Yes Yes Yes anal depressor Yes Yes Yes gonad sheath cellsYes Yes Yes gut Yes Yes Yes uterine muscles Yes ? ? uterine sheath cellsNo No Yes spermatheca Yes No Yes tailspike Yes No Yes coelomocytes No NoYes excretory canal No No Yes

EXAMPLE 4

[0158] Expression of Mammalian SERCA in C. elegans.

[0159] Further constructs were made in which the pig SERCA2a cDNA wascloned under the regulation of the C. elegans SERCA promoter. Suitableconstructs can easily be made by replacing the GFP sequences in pGK10 orpGK13 with the coding region of the pig SERCA2a cDNA. The sequence ofthe pig SERCA2a cDNA is shown in SEQ ID NO:7. C. elegans weretransfected with plasmid pGK101, harboring the pig SERCA2a cDNA underthe control of the worm SERCA promoter derived from pGK 10 by injectionof the plasmid at a concentration of 100 ng/μl, resulting in theoverexpression of the pig SERCA2a in all C. elegans muscles. Theoverexpression of this vertebrate SERCA protein results in embryoniclethality, L1 arrest and growth delay, effects which are quite analogousto the overexpression of C. elegans SERCA.

[0160] The pig SERCA2a was also expressed in C. elegans under thecontrol of the myo-2 promoter (pGK201), which is specific for inductionof expression in the pharyngeal muscles. Overexpression of SERCA2a inthe pharyngeal muscles resulted in apparently normal healthy lines,although a slight growth delay was observed. In a pharynx pumping assay,with the fluorescent dye precursor calcein-AM, it was shown that thenematode pumps with a slightly lower efficiency than a wild-type strain.

[0161] Expression in C. elegans of the pig SERCA2a under the regulationof the myo-3 promoter, which directs gene expression in the body wallmuscles, resulted in apparently normal, healthy lines, with no apparentmovement defects.

EXAMPLE 5

[0162] Expression of Mammalian Phospholamban (PLB) in C. elegans.

[0163] Human, humanized and pig PLB fused and not fused to GFP wereexpressed under the myo-2 promoter in the pharyngeal muscles. Thetransfected nematodes appeared sick, showed a reduced growth and aclearly reduced pharynx pumping phenotype. Further generations ofoffspring seem to be healthier and perform in a pharynx pumping assay aswild-type worms.

[0164] Expression of the PLB-GFP fusion protein in the body wallmuscles, was done under the regulation of the myo-3 promoter. Expressionof the fusion protein could clearly be localized to the endoplasmicreticulum and the dense bodies, but no clear phenotype could beobserved.

EXAMPLE 6

[0165] Construction of a Mutated SERCA C. elegans.

[0166] Strategy 1

[0167] The following strategy may be used to isolate a nematode that ismutated in the SERCA gene, using standard selection procedures wellknown in the art. A population of nematodes are mutagenized,preferentially using UV-TMP, and grown for two generations. Themutagenized worms are distributed per 500 over approximately 1152 platesand grown for an additional two generations. DNA is isolated from afraction of the worms from each of these plates and used as a templatefor PCR selection to select for a SERCA gene that has a deletion. From aplate with worms, of which some have been demonstrated to contain aSERCA deletion, new plates are started with fewer worms. Further roundsof PCR selection finally result in the isolation of a heterozygote C.elegans carrying a mutation in the SERCA gene (see Jansen et al., 1997,Nature Genetics 17:119-121). As the above-mentioned experiments haveshown that the expression level of SERCA is important for the survivalof the nematode it is possible that this strategy may result only in theisolation of partial knock-out mutations as heterozygote C. eleganscarrying a severe knock-out mutation in the SERCA gene may not viable.In this situation, strategy 1 based on extrachromosomal expression canbe used to isolate severe knock-out mutations.

[0168] Strategy 2

[0169] Although primary RNAi experiments indicate that the level ofexpression the SERCA protein needs to be fine-tuned for the survival ofthe C. elegans nematode, strains in which the level of SERCA activity isreduced, in particular strains in which SERCA activity is reduced in asingle tissue, are probably still viable. Due to the sensitivity of C.elegans to the level of SERCA activity this could result in arecognisable phenotype, such as reduced pharyngeal pumping, vulva muscledefects, and hence egg laying defects, anal repressor and anal sphincterdefects, and hence defecation defects, and body wall muscle defects, andhence movement defects. Such strains can be used as the basis of screensto identify compounds capable of enhancing or up-regulating the activityof SERCA.

[0170] The expression levels of SERCA in C. elegans can be specificallyreduced by using antisense technology or double stranded RNA inhibition.The use of antisense technology to specifically reduce expression of agiven protein is well known. For the expression of antisense RNA in theworm, the non-coding strand of a fragment of the SERCA gene can beexpressed under the control of the SERCA, myo-2 or myo-3 promoter or anyother promoter. The expression of the antisense SERCA RNA will result inthe inhibition of expression of SERCA.

[0171] Antisense technology can be used to control gene expressionthrough triple-helix formation of antisense DNA or RNA, both of whichmethods are based on binding of a polynucleotide to DNA or RNA. Forexample, the 5′ coding portion or the mature protein sequence, whichencodes for the SERCA protein, is used to design an antisense RNAoligonucleotide of from 10 to 50 base pairs in length. The antisense RNAoligonucleotide hybridises to the mRNA in vivo and blocks translation ofan mRNA molecule into the protein (Okano, J. Neurochem., 56:560 (1991);Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRCPress, Boca Raton, Fla. (1988)). A DNA oligonucleotide is designed to becomplementary to a region of the gene involved in transcription(triple-helix—see Lee et al. Nucl. Acids Res., 6:3073 (1979); Cooney etal., Science, 241:456 (1988); and Dervan et al., Science, 251: 1360(1991), thereby preventing transcription and the production of theprotein.

[0172] In order to perform an antisense experiment in C. elegans, anEcoRI-Hind III fragment of SERCA exon 5 was cloned antisense under thecontrol of the myo-2 promoter, the myo-3 promoter, the SERCA promoter orthe ceh-24 enhancer and injected into C. elegans. These vectors resultin the expression of an antisense SERCA RNA, and hence in inhibition ofSERCA activity.

[0173] As an alternative to the antisense approach, the expression of agiven gene in a cell can also be specifically reduced by introducinginto the cell double stranded RNA corresponding to a region of thetranscript transcribed from the gene. Double stranded RNA can beprepared by cloning an appropriate fragment into a plasmid vectorcontaining opposable promoters. A suitable example is the pGEM7 seriesof vectors from Promega Corporation, Madison, Wis., USA, which containopposable promoters separated by a multiple cloning site. When theplasmid vector is transformed or transfected into a host cell ororganism which expresses the appropriate polymerases, RNA will betranscribed from each of the promoters. As the vector contains twopromoters oriented in the opposite sense, complementary sense andantisense transcripts will be transcribed which will combine to formdouble stranded RNA. The injection of double stranded RNA in C. eleganshas previously been described (Fire et al, Potent and Specific GeneticInterference by Double-Stranded RNA in C. elegans 1998, Nature 391,860-811).

EXAMPLE 7

[0174] Analysis of a C. elegans Mutant (Designated ok190)

[0175] A C. elegans strain mutated in the SERCA gene was kindly providedby R. Barstead (Oklahoma, USA). Heterozygous animals show no defect, buttheir homozygous progeny die as L1. The lethal phenotype can be rescuedby reintroduction of the C. elegans gene by injection of pGK7.

[0176] Using standard PCR protocols the genomic region of ok190 aroundthe deleted area was cloned in the following way:

[0177] A nested PCR was performed on C. elegans genomic DNA using thefollowing primer pairs:

[0178] Outer: SERCA P2: CGAAGAGCACGAAGATCAGACAG (SEQ ID NO:25) SERCA P8:GAGAGGCGGTTGGTTTGGG (SEQ ID NO:26)

[0179] Inner: SERCA P4: CCGTTCGTCATCCTTCTCATTC (SEQ ID NO:27) SERCA P7:CGACAGATGGACCGACGAGC (SEQ ID NO:28)

[0180] Analysis of the nested PCR product by agarose gel electrophoresisshowed that the PCR product in the ok190 strain harbors a deletion of1.7 kbp. (The wild-type PCR product from SERCA P4-SERCA P7 would be 3.4kbp but the observed ok190 PCR product was only 1.7 kbp).

[0181] To enable detailed analysis of the deleted region the PCR productwas cloned into the pCR-XL-TOPO vector (Invitrogen, The Netherlands).The resulting plasmid was designated pKO4. This cloned fragment was thensequenced revealing the exact coordinates of the deleted region. One ofthe breakpoints of the deletion occurred in the intron between exon IVand exon V, the other in exon V, deleting a total of 1702 bp of which1690 bp represent coding sequence.

[0182] The nucleotide sequence of the genomic fragment of C. elegansSERCA bounded by primers SERCA P4 and SERCA P8 is shown in FIG. 4 and asSEQ ID NO: 16. Exon IV and exon V are shown in capitals, intron IV inlower case. The fragment deleted in ok190 is underlined.

EXAMPLE 8

[0183] Construction of a Thapsigarzin Resistant SERCA.

[0184] A mutated C. elegans SERCA gene which encodes mutant proteinresistant to thapsigargin inhibition has been constructed. The mutationis TTC□GTC, which results in a Phe258Val substitution. This is analogousto the substitution Phe256Val in hamsters, which was shown to be 40-foldresistant to thapsigargin inhibition (Yu et al., 1999, Arch. Biochem.Biophys. 15:225-232).

[0185] The mutation was introduced in the gene with the QuickChangeSite-Directed Mutagenesis Kit (Stratagene, Calif., USA). PCR wasperformed on pGK7, according to the instructions supplied by themanufacturer, with the following primers:

[0186] oGK33F256V (CAACAGAAGTTGGACGAAGTCGGAGAGCAACTTTC) (SEQ ID NO:29)

[0187] oGK34F256V (GAAAGTTGCTCTCCGACTTCGTCCAACTTCTGTTG) (SEQ ID NO:30)

[0188] The resulting mutation was screened by EcoRI digestion, as themutation resulted in the disruption of the EcoRI restriction site. Thenew vector was sequenced, and the vector was transfected into C.elegans. The resulting vector was designated pGK28.

[0189] Test Sensitivity of Phe259Val SERCA Mutation

[0190] Several C. elegans transgenic lines where constructed that carrythe thapsigargin resistant SERCA mutant by standard injection of pGK28into the gonad.

[0191] The effect of thapsigargin on worms carrying a pGK28 transgenewas measured in the following way: 10 μl of thapsigargin dissolved inDMSO (5, 2.5, 1, 0.5, 0.25, 0.1, and 0.05 mM respectively) was addedonto a drop of E. coli strain OP50cs2 in 12-well plates. The wells withcompounds were placed at 10□C. overnight, after which 1 to 10 youngadults were added to the wells. The pharynx pumping rate and movementbehaviour was scored for the ten worms after 10 minutes and after onehour (short term effect). Furthermore the wells were scored forprotruding vulva and rectum, production of progeny (few eggs in body)after one day (mid-term-effects), and for progeny after four days (longterm effect)

[0192] Cold-sensitive E. coli strain OP50cs2 was deposited on Mar. 25,1999 in accordance with the provisions of the Budapest Treaty on theInternational Recognition of the Deposit of Microorganisms in theBelgian Coordinated Collections of Microorganisms (BCCM)/Laboratoriumvoor Microbiologie-Bacterienverzameling (LMG) bacteria collection,Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, Gent, Belgium underaccession number LMG P-18934.

[0193] Conclusions

[0194] The results from this experiment confirmed that the Phe259ValpGK28 lines tested are more resistant to thapsigargin. The clearestindication for resistance was that a large fraction of the GFP-animals(the animals harboring pGK28) grew up to adult or L4 while most non-GFP(not harboring or expressing the mutated SERCA) arrested at L1 and L2and never grew up further than L3 (see FIG. 3). Furthermore it wasobserved that nematodes harboring the Phe259Val SERCA mutant hadslightly more progeny than wild-type and that the protruding vulva andrectum-phenotype was very often observed in the wild-type nematodestreated with thapsigargin, whereas these phenotypes were not or wereonly occasionally observed in strain UG530 (strain harboring plasmidpGK28), treated with thapsigargin.

EXAMPLE 9

[0195] Construction of a C. elegans SERCA Mutant cDNA with a PLBRecognition Site.

[0196] Phospholamban is known to interact with the KDDKPV (SEQ ID NO:39)site in mammalian SERCA1 and SERCA2 (Toyofuku et al., J. Biol Chem.1994, 269:22929-22932). SERCA3 does not contain this sequence and doesnot bind phospholamban. SERCA3 does bind phospholamban when the KDDKPV(SEQ ID NO:39) sequence is introduced, while SERCA2 can no longer bindphospholamban when this sequence is mutated (Toyofuku et al., J. BiolChem. 1994, 269:22929-22932). Phospholamban also interacts withtransmembrane helix TM6, which is identical in all three mammalian SERCAgenes (Asahi et al., J. Biol. Chem. 1999, 274:32855-32862).

[0197] The C. elegans SERCA gene does not contain the KDDKPV (SEQ IDNO:39) sequence, but the TM6 domain is identical to mammalian SERCA. Avariant of C. elegans SERCA containing the KDDKPV (SEQ ID NO:39)recognition site was constructed using standard site directedmutagenesis technology (QuikChange Site-Directed Mutagenesis Kit ofStratagene). The primers oGK118 and oGK119 and plasmid pGK28 were usedto obtain a plasmid designated pGK115 containing thapsigargin-resistantC. elegans SERCA with the KDDKPV (SEQ ID NO:39) site.

[0198] oGK118:GCCAGTCGGAAAGGTTTCCAAGGACGACAAGCCAGTTAACCCAGCT GCTGGAGAATT(SEQ ID NO:31)

[0199] oGK119:AATTCTCCAGCAGCTGGGTTAACTGGCTTGTCGTCCTTGGAAACCTTT CCGACTGGC(SEQ ID NO:32)

[0200] (Nucleotides leading to the mutated SERCA are underlined.)

[0201] Plasmid pGK115 was introduced into C. elegans using standardtechniques. Introduction of this mutant SERCA into C. elegans results ina more efficient interaction between the C. elegans SERCA (here themutant) and vertebrate PLB. Introduction of a KDDKPV (SEQ ID NO:39)mutant into a C. elegans strain which is mutant for SERCA, such as theok190 strain, results in a strain which is directly useful forperforming screens to select for compounds that alter the interaction ofSERCA with PLB and hence that alter the activity of SERCA. Since pGK115also contains the thapsigargin resistance mutation, it can also beexpressed in a wild-type C. elegans for use in screens to select forcompounds that alter the interaction of SERCA with PLB and hence thatalter the activity of SERCA. In such a screen, thapsigargin should beadded to differentiate between activity of the endogeneous SERCA and theintroduced double mutant SERCA.

EXAMPLE 10

[0202] Construction of Fusion Proteins between C. elegans SERCA andVertebrate SERCA.

[0203] The introduction of vertebrate SERCA in C. elegans, the latterbeing a SERCA mutant such as ok190 or a wild-type strain where theendogenous SERCA is inhibited for example by RNAi technology, willresult in rescue of the mutant phenotypes, but maybe not to the fullextent. This could be due, for example, to different kinetic propertiesof C. elegans and vertebrate SERCA, or to interaction with otherpartners than phospholamban. Using fusion proteins will overcome thisproblem. A fusion protein may be constructed that has sufficientproperties of the C. elegans SERCA for rescue of the mutant phenotype,and has those vertebrate SERCA properties sufficient in a screen toselect for compounds that alter the vertebrate SERCA activity.

[0204] At least four types of fusion proteins are contemplated:

[0205] 1) A fusion protein harboring the N-terminal end of the C.elegans and the C-terminal part of a vertebrate SERCA

[0206] 2) A fusion protein harboring the N-terminal part of a vertebrateSERCA and the C-terminal part of the C. elegans SERCA

[0207] 3) A fusion protein harboring the C- and N-terminal part of theC. elegans SERCA and an internal part of a vertebrate SERCA. Thisconstruction can be considered as a variant of the KDDKPV (SEQ ID NO:39)mutation described above.

[0208] 4) A fusion protein harboring the C- and N-terminal part of avertebrate SERCA and an internal part of the C. elegans SERCA

[0209] Such fusion proteins can easily be constructed using standardmolecular techniques.

[0210] A SERCA fusion protein of type 1 has been made in the followingway:

[0211] A PCR reaction was performed on plasmid pGK110 (harboring the pigthapsigargin resistant SERCA2A) using primers oGK108 and oGK109.

[0212] oGK108: GACCGTACGAAATTTTCAGGAAAGGAATGCAGAAAATGCC (SEQ ID NO:33)

[0213] oGK109: CCCCGGCCGGCCTTACTCCAGTATTGCAGGTTCCAGG (SEQ ID NO:34)

[0214] The resulting 2701 bp PCR fragment was digested with BsiWI andEagI and cloned in the 10131 bp fragment of pGK8 (containing genomic C.elegans SERCA) cut at the same sites. The resulting vector wasdesignated pGK114.

EXAMPLE 11

[0215] Construction of Phospholamban Mutants that Show AlteredInteraction with SERCA.

[0216] The interaction of phospholamban with SERCA has been describedvery extensively in the literature. Furthermore mutants of PLB have beendescribed that have an enhanced or a diminished interaction with SERCAand hence have a stronger or weaker inhibitory effect on SERCA (Toyofukuet al., J. Biol. Chem 1993, 269:3088-3094; Kimura et al., J. Biol. Chem.1996, 271:21726-21731; Kimura et al., J. Biol. Chem. 1997,272:15061-15064; Kimura et al., J. Biol. Chem. 1998, 273:14238-14241).

[0217] Introduction of a PLB mutant with an altered inhibition of SERCAin C. elegans can improve the basic screen to select for compounds thatalter the interaction of PLB and SERCA in such a way that the parametersof the screen can be fine-tuned exactly as is most useful, allowingscreening for more specific compounds directed to the PLB SERCAinteraction.

[0218] PLB mutations can easily be made using standard site directedmutagenesis techniques as described above, and as known in the art.

[0219] One phospholamban mutant of particular interest is Ser16Ala. Inintact beating hearts or isolated cardiac myocytes, serine16 becomesphosphorylated by cAMP-dependent protein kinase upon stimulation withisoproterenol. This leads to increased cardiac relaxation due todecreased inhibition. A phospholamban mutant for this phosphorylationsite thus lacks cAMP-dependent protein kinase-mediated regulation(Simmerman et al., J. Biol. Chem. 1986, 261:13333-13341; Wegener et al.,J. Biol. Chem. 1989, 264:11468-11474; Kuschel et al., Am. J. Physiol.1999, 276:H1625-H1633).

EXAMPLE 12

[0220] Cloning of Pig PLB, Construction of Humanized Pig PLB.

[0221] Pig PLB cDNA was cloned from pGEM7PigPLB (Wuytack, personal gift)by PCR amplification using the primer combinations listed below. PCRamplification was performed using standard procedures (PCR, A practicalapproach, ed. by M. J. McPherson, P. Quirke and G. R. Taylor, 1993,Oxford University Press. Summary of primer combinations:

[0222] oGK51-oGK55: pg PLB, including stop codon

[0223] oGK51-oGK56: pig PLB, excluding stop codon (open ended)

[0224] oGK52-oGK55: humanized pig PLB, including stop codon

[0225] oGK52-oGK56: humanized pig PLB, excluding stop codon (open ended)

[0226] oGK51 and oGK52 contain an XbaI site for cloning

[0227] oGK55 and oGK56 contain an Asp718 site for cloning

[0228] oGK52 contains T-to-G point mutation compared to pig PLB cDNA soas to introduce a D-to-E amino acid substitution at position 2 of PLB.Since this is the only difference between the human and pg PLB proteins,the resultant polypeptide is the same as the human PLB sequence (NB thepoint mutated cDNA does not have the same sequence as the human PLB cDNAbut encodes a protein having identical amino acid sequence to human PLB,hence it is referred to as a humanized pig PLB cDNA). Sequences of theprimers are as follows:

[0229] oGK51: GCTCTAGATGGATAAAGTCCAATACCTCAC (SEQ ID NO:35)

[0230] oGK52: GCTCTAGATGGAGAAAGTCCAATACCTCAC (SEQ ID NO:36)

[0231] oGK55: GGGGTACCTCAGAGAAGCATCACGATGATG (SEQ ID NO:37)

[0232] oGK56: GGGGTACCATGAGAAGCATCACGATGATGCAAATC (SEQ ID NO:38)

[0233] pGK202 was constructed by cloning the oGK51-oGK55 PCR fragmentdigested with XbaI and Asp718 into pPd96.48 digested with the sameenzymes. The vector expresses pig PLB under the control of the myo-2promoter.

[0234] pGK204 was constructed by cloning the oGK51-oGK56 PCR fragmentdigested with XbaI and Asp718 into pGK203 digested with the sameenzymes. The vector expresses the pig PLB fused to GFP under the controlof the myo-2 promoter.

[0235] pGK205 was constructed by cloning the oGK52-oGK55 PCR fragmentdigested with XbaI and Asp718 into pPD96.48 digested with the sameenzymes. The vector expresses the humanized pig PLB under the control ofthe myo-2 promoter.

[0236] pGK206 was constructed by cloning the oGK52-oGK56 PCR fragmentdigested with XbaI and Asp718 into pGK203 digested with the sameenzymes. The vector expresses the humanized pig PLB fused to GFP underthe control of the myo-2 promoter.

[0237] pGK302 was constructed by cloning the oGK51-oGK55 PCR fragmentdigested with XbaI and Asp718 into pPD96.52 digested with the sameenzymes. The vector expresses the pig PLB under the control of the myo-3promoter.

[0238] pGK304 was constructed by cloning the oGK51 -oGK56 PCR fragmentdigested with XbaI and Asp718 into pGK303 digested with NheI-Asp718. Thevector expresses the pig PLB fused to GFP under the control of the myo-3promoter.

[0239] pGK305 was constructed by cloning the oGK52-oGK55 PCR fragmentdigested with XbaI and Asp718 intointo pPD96.52 digested withNheI-Asp718. The vector expresses the humanized pig PLB under thecontrol of the myo-3 promoter.

[0240] pGK306 was constructed by cloning the oGK52-oGK56 PCR fragmentdigested with XbaI and Asp718 into pGK303 digested with NheI-Asp718. Theresulting vector expresses the humanized pig PLB fused to GFP under theregulation of the myo-3 promoter.

EXAMPLE 13

[0241] Inhibition of SERCA by Compounds.

[0242] Several compounds are known to inhibit the function of SERCA,such as cyclopiazonic acid, cyproheptadine, thapsigargin, 2,5-di(tert-butyl)-1,4-benzohydroquinone, 2.4-benzoquinone, and vanadate.Other compounds are known to activate the activity of SERCA, such asdiethylether, gingerol, and 1-(3,4-dimethoxyphenyl)-3-dodecanone. Stillother compounds have a dual activity, they stimulate SERCA at lowconcentrations, but inhibit at high concentrations, such asphenothiazines, and pentobarbital.

[0243] Using two kinds of assays, the optimal concentration of compoundsthat inhibit the activity SERCA has been determined. The first assay isdesignated the drop or plate assay in which the nematodes are fed E.coli strains pre-loaded with the compound. In a second assay, thecompound is administrated to the worm in liquid culture.

[0244] Plate Assay

[0245] A standard plate drop assay is performed according to thefollowing protocol. 4 ml NGM agar (see “The nematode C. elegans” Ed. byWilliam B. Wood and the Community of C. elegans Researchers, CSHL Press,1988, pg589) is into 3 cm plates and seeded with approximately 5 μl ofan E. coli overnight culture and grown preferably for one week at roomtemperature. Approximately 10 μl of test compound dissolved in DMSO orother suitable solvent is pipetted onto the bacterial lawn so that thelawn is covered completely. After overnight soaking in or compound, oneC. elegans (L4 stage) per plate is put onto the bacterial lawn. Platesare incubated at 21° C. and checked after some hours. Plates are checkedagain after 4 days for phenotypes of the F1 progeny (control shows allstages up to gravid hermaphrodites).

[0246] Thapsigargin at various concentrations (5 μM, 2.5 μM and 1.25 μM)causes the nematode to stop pharynx pumping within 10 min. Within anhour the worms restart pumping, although at a low level. The worms arepale and thin and have a stow and irregular movement, with an increasedamplitude. No plate drop response is observed, and the worms show poorbacking, reduced pumping and strong constipation. The worms have adefective gonad with only very few eggs, and a protruding vulva. Someworms also have a protruding rectum. Progeny reaches L2 stage only afterfour days, and the brood size is very small. Lower concentrations ofthapsigargin (0.5 μM, 0.25 μM, 0.125 μM) still cause reduced brood size.

[0247] 2,5-di-tert butylhydroquinone at a concentration of 500 μMresulted in pale, starved, thin worms with slow movement, defectivegonad, constipated and reduced brood size.

[0248] Cyclopiazonic acid at a concentration of 500 μM resulted innematodes that lay still or move slowly after one hour. The worms showedstrong avoidance and after 24 hours they look starved, pale and thin,with only a few eggs in the body, a defective gonad, and reduced broodsize. A delayed growth of the F1 generation was observed.

[0249] Thapsigargicin at 500 μM, 125 μM, 31 μM, 10 μM, 5 μM resulted innematodes with similar phenotypes to those described above forthapsigargin at 5 μM, 2.5 μM, 1.25 μM. Lower concentrations ofthapsigargicin (3 μM and 1.5 μM) caused a slightly reduced brood size.

[0250] Thapsigargin-epoxide did not result in a clear observable effect,even at the highest concentration tested (1 mM drop, 5 μM endconcentration).

[0251] 1,4-benzoquinone did not result in a clear observable effect,even at the highest concentration tested (100 mM drop, 500 μM endconcentration).

[0252] Liquid

[0253] Thapsigargin at 100, 50 and 20 μM resulted in small worms whichshow slow and loopy movement. They had a protruding vulva, and noprogeny (or no progeny that grows up) were observed. At lowerconcentrations of 10 μM and 5 μM a reduced number of progeny and delayedgrowth could be observed.

[0254] 2,5-di-tert butylhydroquinone at a concentration of 1 mM resultedin progeny exhibiting delayed growth and the worms be observed to bethinner than ‘normal’ worms.

[0255] Cyclopiazonic acid at a concentration of 1 mM resulted in pale,thin worms with a slow movement and a very strongly reduced brood size.At lower concentrations of 0.5 mM, growth delay was observed.

[0256] Thapsigargicin at 1000 μM, 250 μM, 62.5 μM and 16 μMconcentrations resulted in small worms with slow and loopy movement, aprotruding vulva, and no progeny (or no progeny that grows up) wereobserved. At lower concentrations of 10 μM, delayed growth and reducedprogeny were observed.

[0257] The effect of thapsigargin on progeny of wild-type strains wastested with the liquid assay: On an average of 12 worms, the number ofprogeny for the different concentrations is summarized in FIG. 1.

[0258] The effect of thapsigargin was also tested on progeny ofwild-type strains using the plate assay: On an average of 12 worms thenumber of progeny at different concentrations is summarized in FIG. 2.

[0259] The effect of thapsigargin on the production of progeny wasdetermined for a number of different C. elegans strains. The numbers ofprogeny produced following thapsigargin treatment was counted for anaverage of 15 animals, the results are summarised as follows:

[0260] unc-31: control: 132 0.5 mM: 35 1 mM: 5,6

[0261] srf-3: control: 50 1 mM :18,3

[0262] The effect of thapsigargin on pharynx pumping behaviour was alsodetermined. In wild-type worms, all animals stopped pumping after 10minutes. In mutant strain unc-31 at a concentration of 1 mMthapsigargin, all worms stopped pumping after 10 minutes, some startagain after half an hour, but pumping is only one third of normal speed.

[0263] In summary, the above experiments demonstrate that inhibition ofC. elegans SERCA activity using thapsigargin or other chemicalinhibitors of SERCA results in worms with recognisable phenotypiccharacteristics, including paleness, reduced growth, reduced rate ofpharynx pumping and reduced numbers of progeny.

EXAMPLE 14

[0264] Screening for Antagonists of a Compound (Thapsigargin)

[0265] The compound thapsigargin is known to inhibit the activity ofSERCA. The SERCA protein pumps calcium into the sarco/endoplasmicreticulum and provides the cell with an internal storage of calcium. Theinternal storage of calcium is important for muscle activity. In C.elegans, inhibiting SERCA activity by applying thapsigargin to the wormresults in a decrease in the pharynx pumping rate. Another featureobserved by the action of thapsigargin on the nematode worm C. elegansis decreased movement, which is a result of the inhibition of SERCAactivity of the body wall muscles.

[0266] A pharynx pumping screen has been developed to screen forchemical substances that suppress the activity of thapsigargin on SERCA.In this screen the pumping rate of the pharynx is measured indirectly byadding a marker molecule precursor such as calcein-AM to the medium andmeasuring the formation of marker dye in the C. elegans gut. Calcein-AMis cleaved by esterases present in the C. elegans gut to releasecalcein, which is a fluorescent molecule. The pumping rate of thepharynx will determine how much medium will enter the gut of the worm,and hence how much calcein-AM will enter the gut of the worm. Thereforeby measuring the accumulation of calcein in the nematode gut, detectableby fluorescence, it is possible to determine the pumping rate of thepharynx.

[0267] A standard pharynx pumping screen may be carried out as follows:

[0268] 1) Dispense substantially equal numbers of C. elegans nematodesinto the wells of multi-well assay plates. A ‘worm dispenser’ apparatus,e.g. the device commercially available from Union Biometrica, Inc,Somerville, Me., USA which has properties analogous to flow cytometers,such as fluorescence activated cell scanning and sorting devices (FACS),may be used for this purpose. Typically, 40+/−5 worms are added to eachwell of the microtiter plate.

[0269] 2) Thapsigargin is added to the worms at an inhibitoryconcentration and calcein-AM is added at a concentration of 5-10 μM.

[0270] 3) The chemical substances to be selected are added. Controlwells are also set up containing thapsigargin alone with no secondchemical substance. The chemical substances are typically made up inDMSO. Any other solvent can be used for this purpose, but most selectedchemical substances appear to be soluble in DMSO. The chemical substanceis added in the wells at various concentrations. but preferentially aconcentration between 3 to 30 μM is chosen as this gives the clearestresults. It possible to screen for dosage effects by varying theconcentration of the chemical substance from less than 1 μM up to 100μM.

[0271] The concentration of the DMSO should not be too high andpreferentially should not exceed 1%, more preferentially theconcentration of the DMSO should not exceed 0.5% and even morepreferentially, the concentration of the DMSO is lower than 0.3%.

[0272] 4) Fluorescence intensity is measured using a multi-well platereader (e.g. Victor2, Wallac Oy, Finland) with following settings:Ex/Em=485/530.

[0273] Wells harboring a chemical substance where the measuredfluorescence is higher than in the control wells containing no chemicalsubstance are scored. These wells harbor a chemical substance that is anantagonist of the thapsigargin activity, as the inhibitory activity ofthapsigargin is suppressed. Chemical substances thus identified mayinhibit directly the activity of thapsigargin, or stimulate the activityof SERCA, or have an enhancer activity on the SERCA pathway, and henceon the calcium biology of the organism.

[0274] Chemical substances selected in this screen as antagonists ofthapsigargin are considered as potential therapeutics, or as hits forthe further development of therapeutics in the disease areas which arethe cause of a malfunction of the calcium biology of the organism.Examples of disease areas for which these therapeutics are useful arecardiac hypertrophy, cardiac failure, arterial hypertension, Type 2diabetes and Brody disease.

[0275] In the example given above, thapsigargin is used as an example ofa compound having a defined phenotypic effect on C. elegans as a resultof inhibition of SERCA activity. It will be appreciated that other SERCAinhibitors which have an inhibitory activity on the pharynx pumping ratemay be used in analogous screens with equivalent effect.

EXAMPLE 15

[0276] Screening for Chemical Substances in Transgenic, Mutant andHumanized Animals (SERCA-PLB)

[0277] An increase of the internal storage of calcium is generalconsidered to be important for the strength of muscle contraction, andconsequently an improvement or increase of this muscle contraction canbe realized by enhancing SERCA activity. Chemical substances thatenhance SERCA activity or inhibit the SERCA-PLB interaction areconsidered as potential therapeutics, or as hits for the furtherdevelopment of therapeutics in the disease areas which are the cause ofa malfunction of the calcium biology of the cell or organism. Examplesof disease areas where an increase of SERCA activity may be beneficialare cardiac hypertrophy, cardiac failure, arterial hypertension, Type 2diabetes and Brody disease.

[0278] The different SERCA genes and isoforms which are associated withdifferent types of diseases; SERCA2 and PLB are associated withcardio-vascular diseases, SERCA1 and sarcolipin are associated withskeletal-muscle diseases, and three SERCA genes have been associatedwith non-insulin-dependent diabetes mellitus.

[0279] In order to perform screens to identify chemical substances whichmodulate the activity of SERCA pathways SERCA genes and PLB have beenexpressed in C. elegans. The expression of these genes can be regulatedunder the control of several specific promoters with the followingactivities:

[0280] a) The C. elegans myo-2 promoter which promotes expression in thepharynx

[0281] b) The C. elegans SERCA promoter which promotes expression in theC. elegans muscles, including the pharynx, the vulva muscles and thebody wall muscles.

[0282] The following transgenics were constructed:

[0283] a) pig and/or human SERCA under the SERCA and/or myo-2 promoter.

[0284] b) pig and/or human SERCA under the SERCA and/or myo-2 promoterin a C. elegans mutated for the C. elegans SERCA (Knock-outs andselected mutants).

[0285] c) pig and/or human PLB under the SERCA and/or the myo-2promoter.

[0286] d) pig and/or human PLB under the SERCA and/or the myo-2 promoterin a C. elegans mutated for the C. elegans SERCA (Knock-out and selectedmutants).

[0287] e) pig and/or human PLB-GFP fusion under the SERCA and/or themyo-2 promoter.

[0288] f) pig and/or human PLB-GFP fusion under the SERCA and/or themyo-2 promoter in a C. elegans mutated for the C. elegans SERCA(Knock-outs and selected mutants).

[0289] g) pig and/or human SERCA under the SERCA promoter and pig and/orhuman PLB under the myo-2 promoter.

[0290] h) pig and/or human SERCA under the SERCA promoter and pig and/orhuman PLB under the myo-2 promoter in a C. elegans mutated for the C.elegans, SERCA (Knock-out and selected mutants).

[0291] i) pig and/or human SERCA under the SERCA promoter and pig and/orhuman PLB-GFP under the myo-2 promoter.

[0292] j) pig and/or human SERCA under the SERCA promoter and pig and/orhuman PLB-GFP under the myo-2 promoter in a C. elegans mutated for theC. elegans SERCA (Knock-out and selected mutants).

[0293] Some of these constructed transgenic and mutant worms show aclear change in pharynx pumping rate as can be measured by thefluorescence of calcein in the gut using the calcein-AM pharynx pumpingassay. Some of these strains were considered to be useful for furtherscreen development. To perform the pharynx pumping assay, the transgenicand mutant animals were placed in the wells of multi-well plates.Calcein-AM and chemical substances under test were then added. Thefluorescence of the calcein formed in the gut was measured in amulti-well plate reader set to measure fluorescence. Chemical substancesthat altered the properties of the pharynx pumping rate, and hencealtered the function and activity of the SERCA pathway were selected forfurther analysis, and can be considered as potential compounds fortherapeutic use, or as hits for the further development of therapeutics.

[0294] A analogous experiment can be performed with the SERCA1 gene andits regulator Sarcolipin (SLN), to detect chemical substances that altertheir activity and/or regulation.

EXAMPLE 16

[0295] Construction of Plasmids.

[0296] The ‘pPD’ series of vectors were all obtained from the laboratoryof Andrew Fire, see Fire A, Harrison S. W., and Dixon D. A modular setof LacZ fusion vectors for studying gene expression in Caenorhabditiselegans. 1990. Gene 93:189-198. The sequences of these vectors arefreely available at ftp://stein.cshl.org/pub/elegans_vector/).

[0297] pGK301 was constructed by cloning a 3181 bp fragment of pERIItA(F. Wuytack, personal communication) into pPD96.52 digested with thesame restriction enzymes. pGK301 expresses the SERCA2a cDNA under theregulation of the myo-3 promoter.

[0298] pGK201 was constructed by cloning a 480009 bp NheI/SpeI fragmentof pGK301 in pPD96.48 digested with the same enzymes. The vectorexpresses pig SERCA2a under the regulation of the moy-2 promoter.

[0299] pGK101 was constructed by cloning a 4828bp NheI/ApaI fragment ofpGK201 into plasmid pDW2600 digested with the same enzymes. The vectorexpresses the pig SERCA2a cDNA under the regulation of the worm SERCApromoter.

[0300] pDW2600 was constructed by cloning a 5046bp SphI-SmaI fragment ofpGK10 in pPD49.26.

[0301] pGK203 was constructed by cloning the AccI/SpeI fragment ofpPD95.79 into pPD96.48 digested with the same enzymes. This vectorcontains the myo-2 promoter, GFP and unc-54 3′UTR.

[0302] pGK303 was constructed by cloning the Asp718-ApaI fragment ofpPD95.79 into pPD96.52 digested with the same enzymes. This vectorcontains the myo-2 promoter, GFP and unc-54 3′UTR.

[0303] List of Genbank Accession Numbers for SERCA and PLB cDNASequences:

[0304] pig SERCA2a GenBank P11606

[0305] human SERCA1a GenBank AAB 53113

[0306] human SERCA1b GenBank AAB 53112

[0307] human SERCA2a GenBank P16614

[0308] human SERCA2b GenBank P16615

[0309] human SERCA3 GenBank Q93084

[0310] pig PLB GenBank P07473

[0311] human PLB GenBank P26678

[0312] Sequence Listing

[0313] SEQ ID NO:1 is the nucleic acid sequence of a 732 bp EcoRI-HindIIfragment of C. elegans SERCA exon 5. This fragment was cloned into pGEM3for use in RNA inhibition experiments.

[0314] SEQ ID NO:2 is the nucleic acid sequence of a 11207 bp SpeI-MluIfragment of cosmid K11D9. This fragment contains the complete C. elegansSERCA gene with 5631 bp of upstream sequence, the entire coding regionand 1088 bp of downstream sequence. The fragment was cloned into pUC18to give plasmid pGK7.

[0315] SEQ ID NO:3 is the nucleic acid sequence of a 5026 bp fragment ofthe upstream region of C. elegans SERCA, up to and including A of theinitiating ATG. This fragment was cloned into pPD95.79, in fusion withGFP, to give plasmid pGK10.

[0316] SEQ ID NO:4 is the nucleic acid sequence of a 2915 bp fragment ofthe upstream region of C. elegans SERCA, as found in plasmid pGK13.

[0317] SEQ ID NO:5 is the nucleic acid sequence of a 6612 bp fragment ofthe C. elegans SERCA gene containing 5637 bp of upstream sequence andending in exon 4, as cloned in pPD95.75, resulting in pGK12.

[0318] SEQ ID NO:6 is the nucleic acid sequence of the long isoform ofthe C. elegans SERCA cDNA.

[0319] SEQ ID NO:7 is the nucleic acid sequence of the pig SERCA2a cDNA.

[0320] SEQ ID NO:8 is the nucleic acid sequence of the human SERCA2acDNA.

[0321] SEQ ID NO:9 is the nucleic acid sequence of the pig phospholambancDNA.

[0322] SEQ ID NO:10 is the nucleic acid sequence of the C. elegans myo-2promoter.

[0323] SEQ ID NO:11 is the nucleic acid sequence of the C. elegans myo-3promoter.

[0324] SEQ ID NO:12 is the nucleic acid sequence of the C. elegansvulval muscle enhancer. This is an enhancer element from ceh-24 thatdirects gene expression in the vulval muscles (Harfe and Fire, 1998,Developmental 125: 421-429)

[0325] SEQ ID NO:13 is the nucleic acid sequence of humanized pig PLBcDNA.

[0326] SEQ ID NO:14 is the amino acid sequence of pig PLB.

[0327] SEQ ID NO:15 is the amino acid sequence of human PLB andhumanized pig PLB.

[0328] SEQ ID NO:16 is the nucleotide sequence of a genomic fragment ofC. elegans SERCA covered by primers SERCA P4 and SERCA P8.

[0329] SEQ ID Nos: 17-38 are primers used in the accompanying Examples.

[0330] All references disclosed herein are incorporated by reference intheir entirety.

1 39 1 732 DNA Caenorhabditis elegans 1 gaattcgaat cactcaccga gttggccatgatctgcgcta tgtgcaatga ttcatctgtt 60 gattacaatg agaccaagaa gatctacgagaaagtcggag aagccactga aactgctctt 120 atcgttcttg ctgagaagat gaatgttttcggaacctcga aagccggact ttcaccaaag 180 gagctcggag gagtttgcaa ccgtgtcatccaacaaaaat ggaagaagga gttcacactc 240 gagttctccc gtgatcgtaa atccatgtccgcctactgct tcccagcttc cggaggatct 300 ggagccaaga tgttcgtgaa gggagccccagaaggagttc tcggaagatg cacccacgtc 360 agagttaacg gacaaaaggt tccactcacctctgccatga ctcagaagat tgttgaccaa 420 tgcgtgcaat acggaaccgg aagagatacccttcgttgtc ttgccctcgg aaccatcgat 480 accccagtca gcgttagcaa catgaacctcgaagactcta cccaattcgt caaatacgaa 540 caagacatca catttgtcgg agtcgtcggaatgcttgacc ccccaagaac tgaagtttcg 600 gactcgatca aggcttgtaa ccacgctggaatccgtgtca tcatgatcac cggagacaac 660 aagaacaccg ctgaggctat cggaagaagaatcggactct tcggagagaa cgaggatacc 720 actggaaagc tt 732 2 11207 DNACaenorhabditis elegans 2 ctagttttga aatccaaaaa aaaaacaaag ttcaataaaatgttacccaa ttgtgcgatt 60 tttgctttaa aaatacggta cccggtctcg atgcggcaattgtttggtaa atgtaaaagg 120 gtgtgcgcct ttaaagagta ctgtaatttc aatcttccgacactgctgaa tttttattga 180 ctttttgttc attaatttta tatatgattt attggtatgttaaaaaaaca cccattttca 240 aatctattaa aattccacaa caacaaaagt tcgagattacagtacttttt agaggcgcac 300 atcctttttg ggatactaaa caattgtcgc gtcgagaccaggtaccatat ttccaaaaca 360 caatttcgcg tgtaaataaa aaatatcaac ataataatttccatttttcg aaatttaaag 420 ttaatcactt tttggtttag attatgattt cacacgtttttttccttcta gttctctttt 480 ttttgttatt tgcctgaaaa atggtctgaa aacttaggcaatcagcaatg tgtcacataa 540 tttctcccag agaaatccct ttcaacaaaa tctcccggattgacctgtgt gctcgacctt 600 gataaattgg ttggcagctc tctggcttat cttttgagaggaaaaagatc caacaaattt 660 ttatctccct tatccctttt tctcttcatc actaccaataataatagttt tttttttcgt 720 cgcggaagca aaatggcgaa caagtgttgg aataagagtactccagggat ttaagggctg 780 aaagccagtg atttatgagc tccaattttt cagatgttttttcctccatc gcgtatttgt 840 ctaaacattc gattttcttc ctgcttccca acttttcaaatcgaaataaa agagcatctg 900 tcgcttttta tcgatgtgct tctgtgagac taaagaactactcgttttca ctcgttctct 960 ctctctcaac tatcaaagtt ttgttgattg cgtgtgtcagcttccttctt tttattatca 1020 tcttttcatt ggaggaaaaa aataacttct gaagagcaaaagaactaact tcggggaata 1080 cagagaaaat tcctgtaaaa atctggaaat tttttcgcttaactcgaaat atttagtttt 1140 tcactgtgat ttctgggaaa aatcaagaaa tatttgcctaaaacacgagt tttcacatga 1200 aaaatgaatt atttattgat tttttatgga gattacaaaaaagacacacg tgaaactact 1260 gctaccgtag ttgtgtaaac gtagtgttct ctattttagacctgtttaat gtattttttt 1320 gcagttgaaa atttttaaaa atattttagt tatttttaaaaatatttaat ttacaaaata 1380 attagcctga acccatgaaa agatacgtta tatttaatttttaccgtaag actttcaaga 1440 tcgttgcgag acccggcgcc taggtcaaag agcctccctttaaacccatc aacacgtttt 1500 gcctttttca tcgatttttt gcagttcttt tcttctttccaactgatttt tcttcatttt 1560 taaagttttt ttcctcattt ttcccatttg aaattatttaaacacgtgca accagctggt 1620 aacatgtgtc acatgccgtt atctaacttc aaaacagtacatttccgatc acacgtcccc 1680 cgcgccgagt tttatagttt cattaataac ttttcggtttttgataatac taattgagtt 1740 ttattaattg tttccatatt catctagcac tttgacctgtccttcttcga attctcaaat 1800 atttgcactc tgggtttagg tgtgaaaaga attgtcgtcattaagcgggg catccggggc 1860 accgaaaaaa gccctccgat tttaacgaat ttgagataaagttggagaga gagcccagtg 1920 tttgcttgcc caagatatat atcttggatt tatcaattactgtttgtcaa cctgtcgccg 1980 gcgccccctt tttgctcttg ctcccacgcc ccgagattgaatttcaattt tatttcgaag 2040 taagtctctt gattgtttcg aaaatccgat gacagttttcattacttttt tgtctgttga 2100 ttttgtaggg aaacattgaa atttttctga tctttctttgatcttatgat ttttcattta 2160 ttccaattaa aaaaaattag cgcattcaga accagagtgaagcttgagat gttgtaggtt 2220 tatcaaaaga tcaaaatctc gaattccttc gaaatgtttttagttttcga cttccgtgtg 2280 atttctagcg atcctgacag agatcactga attttaatgttatcgagatt gttgtgtagg 2340 ctccatctcc tctctgaagc ttctgatttt gccgaaagtctagttacttg ccgactgctg 2400 acactaggat atcccactac cgtacccatt gttggatccgtactctgctg cgacttcttc 2460 tctgtttcac gtgaacctcc gggatcgtcg gtaagccccgcccgttatct gtgccaactt 2520 gtcttcgtgc cctcgagcga cgagctcatt caatcacgccacgacctccg tctggacaga 2580 tgctctcatt gtctctgcgt ctccaagtat tcgtcacactatctcatgca ttctattcaa 2640 aacgcgagag aaagcgcggg aacgagagag agttcagacagatcgaactt gtttttatcc 2700 ccccccccct cgtccggctg cagagcaaaa aaatactgcttttccttgca aaattcggtg 2760 ctttcttcaa agagaaactt ttgaagtcgg cgcgagcatttccttctttg acttctctct 2820 ttccgccaaa aagcctagca tttttattga taatttgattacacacactc agagttcttc 2880 gacatgataa agtgtttcat tggcactcgc cctaacagtacatgacaagg gcggattatt 2940 atcgatcgat attgaagaca aactccaaat gtgtgctcattttggagccc cgtgtggggc 3000 agctgctctc aatatattac tagggagacg aggagggggaccttatcgaa cgtcgcatga 3060 gccattcttt cttctttatg cactctcttc actctctcacacattaatcg attcatagac 3120 tcccatattc cttgatgaag gtgtgggttt ttagctttttttcccgattt gtaaaaggaa 3180 gaggctgacg atgttaggaa aaagagaacg gagccgaaaaaacatccgta gtaagtcttc 3240 cttttaagcc gacacttttt agacagcatt cgccgctagttttgaagttt aaattttaaa 3300 aaataaaaat tagtttcaat tttttttaat tactaaataggcaaaagttt tttcaagaac 3360 tctagaaaaa ctagcttaat tcatgggtac tagaaaaattcttgttttaa atttaatatt 3420 tatcttaaga tgtaattacg agaagctttt ttgaaaattctcaattaaaa gaatttgccg 3480 atttagaata aaagtcttca gaaatgagta aaagctcaaattagaagttt gtttttaaag 3540 gaaaaacacg aaaaaagaac actatttatc ttttcctccccgcgtaaaat tagttgttgt 3600 gataatagtg atccgctgtc tatttgcact cggctcttcacaccgtgctt cctctcactt 3660 gacccaacag gaaaaaaaaa catcacgtct gagacggtgaattgccttat caagagcgtc 3720 gtctctttca cccagtaaca aaaaaaattt ggtttctttactttatattt atgtaggtca 3780 caaaaaaaaa gtgatgcagt tttgtgggtc ggttgtctccacaccacctc cgcctccagc 3840 agcacacaat catcttcgtg tgttctcgac gattccttgtatgccgcggt cgtgaatgca 3900 ccacattcga cgcgcaacta cacaccacac tcactttcggtggtattact acacgtcatc 3960 gttgttcgta gtctcccgct ctttcgtccc cactcactcctcattattcc ccttggtgta 4020 ttgatttttt ttaaatggta caccactcct gacgtttctaccttcttgtt ttccgtccat 4080 ttagatttta tctggaaatt tttttaaaat tttaggccagagagttctag ttcttgttct 4140 aaaagtctag gtcagacata cattttctat ttctcatcaaaaaaaaagtt gataaagaaa 4200 actggttatt cagaaagagt gtgtctcgtt gaaattgattcaaaaaaaaa ttcccacccc 4260 tcgcttgttt ctcaaaatat gagatcaacg gattttttccttctcgattc aattttttgc 4320 tgcgctctgt ctgccaaagt gtgtgtgtcc gagcaaaagatgagagaatt tacaaacaga 4380 aatgaaaaaa agttggccaa ataatgaagt tttatccgagattgatggga aagatattaa 4440 tgttctttac ggtttggagg ggagagagag atagattttcgcatcaaact ccgcctttta 4500 catgtctttt agaatctaaa atagattttt ctcatcatttttaatagaaa atcgagaaat 4560 tacagtaatt tcgcaatttt cttgccaaaa atacacgaaatttgtgggtc tcgccacgat 4620 ctcggtctta gtggttcatt tggtttaaaa gtttataaaatttcaaattc tagtgtttaa 4680 tttccgcata attggaccta aaatgggttt ttgtcatcattttcaacaag aaatcgtgaa 4740 aatcctgttg tttcgcaatt ttcttttcaa aaatacacgaaatatatggt aatttcccga 4800 aatattgagg gtctcgccac gatttcagtc acagtggccaggatttatca cgaaaaaagt 4860 tcgcctagtc tcacatttcc ggaaaaccga atctaaattagttttttgtc atcattttga 4920 acaaaaaatc gagacatccc tatagtttcg caattttcgtcgcttttctc tccaaaaatg 4980 acagtctaga attaaaattc gctggaactg ggaccatgatatcttttctc cccgtttttc 5040 attttatttt ttattacact ggattgacta aaggtcaccaccaccgccag tgtgtgccat 5100 atcacacaca cacacacaca caatgtcgag attttatgtgttatccctgc ttgatttcgt 5160 tccgttgtct ctctctctct attcatcttt tgagccgagaagctccagag aatggagcac 5220 acaggatccc ggcgcgcgat gtcgtcggga gatggcgccgcctgggaagc cgccgagaga 5280 tatcagggaa gatcgtctga tttctcctcg gatgccacctcatctctcga gtttctccgc 5340 ctgttactcc ctgccgaacc tgatatttcc cgttgtcgtaaagagatgtt tttattttac 5400 tttacaccgg gtcctctctc tctgccagca cagctcagtgttggctgtgt gctcgggctc 5460 ctgccaccgg cggcctcatc ttcttcttct tcttctctcctgctctcgct tatcacttct 5520 tcattcattc ttattccttt tcatcatcaa actagcatttcttactttat ttattttttt 5580 caattttcaa ttttcagata aaaccaaact acttgggttacagccgtcaa catggaggac 5640 gcgcatgcca aagacgccaa tgaggtactt ttatagtttttaaattttag tttttaatac 5700 aatttatttt ccaggtgtgc aaattcttcg gaacgggtccggagggattg actccacagc 5760 aagttgaaac attgaggaac aaatatggag aaaatggttggttttttaca tggatttctc 5820 attaaaaatt gaattttttc cagaaatgcc cgccgaagagggaaaatcac tgtgggagct 5880 gattctcgag caattcgacg atcttctcgt caagattctcctcctcgccg ccatcatctc 5940 gtttgtgctc gcccttttcg aagagcacga agatcagacagaagcagtga cggcgttcgt 6000 cgaaccgttc gtcatccttc tcattcttat tgccaacgcgaccgtcggag tgtggcaggt 6060 aggaacaaca cagacaggcg cacgcgctga aagaaaataagaagaagaag aaaaagcaca 6120 gttgttttct gtgtttttgt agatcaaaag aaaggaactaggagtgattg cacagagaga 6180 gagagagaga aataatgtct ttttgacttg tttttgttggtgagagagat agggaaaaag 6240 agtccctaaa gaaaaaatag tgtaacgggc ggtccggaagaaatgctctt tgcgccgaaa 6300 agtttttgaa aaaagaagaa aatgatgaag gaaaggcgtgcgtcatgagc ttcgcattta 6360 cgtacgcaaa aagtgaggga tatgtgaaaa agatattgggtgatagaata gttgatggat 6420 tgggctgcac tatttgcctc aatttgccac aaatttccatctaatttgtc ataattttcc 6480 aggaacgaaa tgctgaatcg gccatcgaag cgctcaaggaatacgaacca gaaatggcca 6540 aggtcatccg atccggacac cacggaattc agatggttcgcgctaaggaa ctcgtgccag 6600 gagatcttgt cgaagtttca ggttagcaaa aacttttttttttaactttc aaattttaaa 6660 ccatatattt ttcagtcgga gacaagatcc cagccgatctccgtcttgtg aagatctact 6720 ccaccaccat ccgtatcgat cagtccatcc tcaccggagaatctgtgtct gttatcaagc 6780 acaccgactc tgtgccagat ccacgcgctg ttaaccaggacaagaagaat tgtctgttct 6840 cgggaaccaa tgtcgcatct ggaaaggctc gtggaatcgtcttcggaacc ggattgacca 6900 ctgaaatcgg aaagatccgt accgaaatgg ctgagaccgagaatgagaag acaccacttc 6960 aacagaagtt ggacgaattc ggagagcaac tttccaaggttatctctgtt atttgcgttg 7020 ctgtttgggc tatcaacatt ggacatttca acgatccagctcacggtgga tcatgggtta 7080 agggagcaat ctactacttc aaaatcgccg ttgctcttgccgtcgctgct attccagaag 7140 gacttccagc tgtcatcacc acgtgccttg ccctcggaactcgccgtatg gccaagaaga 7200 acgctattgt aagatccctt ccatccgtcg aaactcttggatgcacatct gttatctgct 7260 ctgacaagac tggaactctc accaccaacc agatgtctgtgtcaaagatg ttcatcgctg 7320 gacaagcttc tggagacaac atcaacttca ccgagttcgccatctccgga tccacctacg 7380 agccagtcgg aaaggtttcc accaatggac gtgaaatcaacccagctgct ggagaattcg 7440 aatcactcac cgagttggcc atgatctgcg ctatgtgcaatgattcatct gttgattaca 7500 atgagaccaa gaagatctac gagaaagtcg gagaagccactgaaactgct cttatcgttc 7560 ttgctgagaa gatgaatgtt ttcggaacct cgaaagccggactttcacca aaggagctcg 7620 gaggagtttg caaccgtgtc atccaacaaa aatggaagaaggagttcaca ctcgagttct 7680 cccgtgatcg taaatccatg tccgcctact gcttcccagcttccggagga tctggagcca 7740 agatgttcgt gaagggagcc ccagaaggag ttctcggaagatgcacccac gtcagagtta 7800 acggacaaaa ggttccactc acctctgcca tgactcagaagattgttgac caatgcgtgc 7860 aatacggaac cggaagagat acccttcgtt gtcttgccctcggaaccatc gataccccag 7920 tcagcgttag caacatgaac ctcgaagact ctacccaattcgtcaaatac gaacaagaca 7980 tcacatttgt cggagtcgtc ggaatgcttg accccccaagaactgaagtt tcggactcga 8040 tcaaggcttg taaccacgct ggaatccgtg tcatcatgatcaccggagac aacaagaaca 8100 ccgctgaggc tatcggaaga agaatcggac tcttcggagagaacgaggat accactggaa 8160 aagcttacac tggacgtgaa tttgacgatc ttccaccagagcaacaatct gaagcctgcc 8220 gcagagctaa gcttttcgcc cgtgtcgagc catctcacaagtccaagatt gtcgatatcc 8280 ttcaatccca gggagagatt actgctatga ccggagacggagtcaacgac gctccagctt 8340 tgaagaaggc cgaaatcgga atttctatgg gatcaggaactgctgtcgcc aagtctgcat 8400 ctgaaatggt tcttgctgac gataacttcg catccattgtgtctgctgtc gaagaaggac 8460 gtgctattta caacaacatg aaacaattca tcagatatctcatctcatct aacgtcggag 8520 aagtcgtctc catcttcatg gtcgccgcac tcggaattccagaggctctc attccagttc 8580 aacttctctg ggttaacttg gtcactgacg gtcttccagccactgctctc ggattcaatc 8640 caccagatct tgacattatg gacagacatc cacgttcagccaacgatgga ctcatctctg 8700 gatggctctt cttcagatat cttgctgtcg gaagtacgtttaaaaaattc ccctaaaaaa 8760 gtataattct aaaattgaaa ttttccagcc tacgtcggagttgccaccgt cggagcctca 8820 atgtggtggt tcttgttgta cgaggaggga ccacagatcacctactacca gctcactcac 8880 tggatgagat gtgaaatcga gccagacaac tttgccgatcttgactgcgc cgtattcgag 8940 gacaatcacc cgaacgccat ggctctgtcc gtgcttgtcaccattgagat gctcaacgcc 9000 atcaactcac tttccgagaa tcaatcgctt ttagtgatgccaccatggaa gaacatctgg 9060 ctgatggccg ccatttccct ttcgatgtct cttcactttgtcattctcta cgttgacatc 9120 atggccacca tcttccaggt atcacaatta atcatatattaatcgaaaca tctaattcaa 9180 atcttcagat cacccctctc aactgggtcg aatggatcgccgtgttgaag atctcactgc 9240 cagtgctcct tctcgatgaa attctcaagt tcatcgccagaaactacatc gacggtaagc 9300 cggagacggt cggcgcgaag gcacgtagtg ccatctcgctgctcgcctgg gtgtctgtga 9360 cgctcgccta ctttgcgtgg atgttgggcc cgtacgccgagctcattaac catgcgctcg 9420 tcggtccatc tgtcgatccg tcgaaattcg acgcggttgtcacgcccgac aagttacata 9480 acgaattgtg attgaagttc ttctaacccc caaaccaaccgcctctcaaa caacttgtga 9540 tgatttctct ttattttctc tctctttctt gttctaatcattttgggcct ttttcccttt 9600 ttctctctgc agtgtgttaa ctgatccata atccttcgtgtaaacccccc tctccctact 9660 tttaggattt cttcctcgtt gctcattgta ttttgtccaaatcgccacaa tttccctaca 9720 aatatatatg ttttttttgc taattttttg tgtttcccttccttcttgtc cactgaaagt 9780 tctacgtctc tcgctctcca catccccatt gttctccccttttttcataa taatttatta 9840 ttatcctttt tttaaattaa tttttgttgc gtgtgaatctattaggagct cacaaataaa 9900 agtgatcctt taaaaaacct tacttccttc tgttttttctctaacctaac caatgtgtct 9960 gttcagggag tgcctctttt ctttaccgaa tggtgtgcaattttgtcgac tgtcgatctc 10020 gtccatggca atgcaggatt tgaaactaaa tttccctggaaaaagaaata attttggtga 10080 ttttcagttg aagctccaat caaggataaa cgcgactaaaaatgacagtg ctccctcaat 10140 cagagtgagc ccagccgccg cccatctcat ttttcagactctttcatatt ttctaagttt 10200 tccaattttt tttcttttgt agtgcgatcg ttttcgtttcgagacccgaa atcgaaagga 10260 tctcttttag agatctttag gatctttttt ctttgctcaactcatcattc tttgtttttt 10320 cttctatatc ctcttgttga cggtgatcag acaaatttgttagaaatatt attacatttc 10380 ctttaggttt cttctattaa aaaaaaagaa aacttctgctaaattcgtgt acgttgtctc 10440 tcccatttct cattaaaaat cgatattaat tgtaatttttggtttgtcct ccagtgtcgt 10500 gtgcgccatc gatggaaata aaaaagtttc aaaactattatagcttttct ttttatgaaa 10560 aatataaaat acaattagaa tgtttttgtt aaatgcgatacggtgtgcgc ctttaaagag 10620 tagagtactg tagttccaaa attttgttgg tgcgggattttcattgattt ttcatcgttt 10680 ttcgacaaaa atatatttat ttattgaaaa aagttaaataaaactattaa aaacacagaa 10740 tttttaacaa attgtgaaaa acacatgaaa aatcgatgacaattctacag taacgaacat 10800 tttgaattac agtaatcttt aaaggcgcgc acacgtttgcatttaattaa aatgtgtcgt 10860 gtcgagaccg actaccacgt ctcgttatta tagaacgagcaattacagcc taacatcaac 10920 tcagaacaaa ccaggatccc acgcaagttt aaaggagcatgctgggtatc acaacgattt 10980 tttgaagaga acgaggcccc acgaaacggg gagcagaacgaaaaggggat ctgcaaaaag 11040 gggatctgca aaaaggggat ctgcgaaaag gggagatatgaaaaggggag atacgaaaag 11100 gggagctggc actgtgccaa acgcacaaaa cgcaatttttctcacgcaac gcacgttgat 11160 ttttgaaatt ttcttctaga agatacgctt aacaacacgcgacgcgg 11207 3 5026 DNA Caenorhabditis elegans 3 ttggttggca gctctctggcttatcttttg agaggaaaaa gatccaacaa atttttatct 60 cccttatccc tttttctcttcatcactacc aataataata gttttttttt tcgtcgcgga 120 agcaaaatgg cgaacaagtgttggaataag agtactccag ggatttaagg gctgaaagcc 180 agtgatttat gagctccaatttttcagatg ttttttcctc catcgcgtat ttgtctaaac 240 attcgatttt cttcctgcttcccaactttt caaatcgaaa taaaagagca tctgtcgctt 300 tttatcgatg tgcttctgtgagactaaaga actactcgtt ttcactcgtt ctctctctct 360 caactatcaa agttttgttgattgcgtgtg tcagcttcct tctttttatt atcatctttt 420 cattggagga aaaaaataacttctgaagag caaaagaact aacttcgggg aatacagaga 480 aaattcctgt aaaaatctggaaattttttc gcttaactcg aaatatttag tttttcactg 540 tgatttctgg gaaaaatcaagaaatatttg cctaaaacac gagttttcac atgaaaaatg 600 aattatttat tgattttttatggagattac aaaaaagaca cacgtgaaac tactgctacc 660 gtagttgtgt aaacgtagtgttctctattt tagacctgtt taatgtattt ttttgcagtt 720 gaaaattttt aaaaatattttagttatttt taaaaatatt taatttacaa aataattagc 780 ctgaacccat gaaaagatacgttatattta atttttaccg taagactttc aagatcgttg 840 cgagacccgg cgcctaggtcaaagagcctc cctttaaacc catcaacacg ttttgccttt 900 ttcatcgatt ttttgcagttcttttcttct ttccaactga tttttcttca tttttaaagt 960 ttttttcctc atttttcccatttgaaatta tttaaacacg tgcaaccagc tggtaacatg 1020 tgtcacatgc cgttatctaacttcaaaaca gtacatttcc gatcacacgt cccccgcgcc 1080 gagttttata gtttcattaataacttttcg gtttttgata atactaattg agttttatta 1140 attgtttcca tattcatctagcactttgac ctgtccttct tcgaattctc aaatatttgc 1200 actctgggtt taggtgtgaaaagaattgtc gtcattaagc ggggcatccg gggcaccgaa 1260 aaaagccctc cgattttaacgaatttgaga taaagttgga gagagagccc agtgtttgct 1320 tgcccaagat atatatcttggatttatcaa ttactgtttg tcaacctgtc gccggcgccc 1380 cctttttgct cttgctcccacgccccgaga ttgaatttca attttatttc gaagtaagtc 1440 tcttgattgt ttcgaaaatccgatgacagt tttcattact tttttgtctg ttgattttgt 1500 agggaaacat tgaaatttttctgatctttc tttgatctta tgatttttca tttattccaa 1560 ttaaaaaaaa ttagcgcattcagaaccaga gtgaagcttg agatgttgta ggtttatcaa 1620 aagatcaaaa tctcgaattccttcgaaatg tttttagttt tcgacttccg tgtgatttct 1680 agcgatcctg acagagatcactgaatttta atgttatcga gattgttgtg taggctccat 1740 ctcctctctg aagcttctgattttgccgaa agtctagtta cttgccgact gctgacacta 1800 ggatatccca ctaccgtacccattgttgga tccgtactct gctgcgactt cttctctgtt 1860 tcacgtgaac ctccgggatcgtcggtaagc cccgcccgtt atctgtgcca acttgtcttc 1920 gtgccctcga gcgacgagctcattcaatca cgccacgacc tccgtctgga cagatgctct 1980 cattgtctct gcgtctccaagtattcgtca cactatctca tgcattctat tcaaaacgcg 2040 agagaaagcg cgggaacgagagagagttca gacagatcga acttgttttt atcccccccc 2100 ccctcgtccg gctgcagagcaaaaaaatac tgcttttcct tgcaaaattc ggtgctttct 2160 tcaaagagaa acttttgaagtcggcgcgag catttccttc tttgacttct ctctttccgc 2220 caaaaagcct agcatttttattgataattt gattacacac actcagagtt cttcgacatg 2280 ataaagtgtt tcattggcactcgccctaac agtacatgac aagggcggat tattatcgat 2340 cgatattgaa gacaaactccaaatgtgtgc tcattttgga gccccgtgtg gggcagctgc 2400 tctcaatata ttactagggagacgaggagg gggaccttat cgaacgtcgc atgagccatt 2460 ctttcttctt tatgcactctcttcactctc tcacacatta atcgattcat agactcccat 2520 attccttgat gaaggtgtgggtttttagct ttttttcccg atttgtaaaa ggaagaggct 2580 gacgatgtta ggaaaaagagaacggagccg aaaaaacatc cgtagtaagt cttcctttta 2640 agccgacact ttttagacagcattcgccgc tagttttgaa gtttaaattt taaaaaataa 2700 aaattagttt caattttttttaattactaa ataggcaaaa gttttttcaa gaactctaga 2760 aaaactagct taattcatgggtactagaaa aattcttgtt ttaaatttaa tatttatctt 2820 aagatgtaat tacgagaagcttttttgaaa attctcaatt aaaagaattt gccgatttag 2880 aataaaagtc ttcagaaatgagtaaaagct caaattagaa gtttgttttt aaaggaaaaa 2940 cacgaaaaaa gaacactatttatcttttcc tccccgcgta aaattagttg ttgtgataat 3000 agtgatccgc tgtctatttgcactcggctc ttcacaccgt gcttcctctc acttgaccca 3060 acaggaaaaa aaaacatcacgtctgagacg gtgaattgcc ttatcaagag cgtcgtctct 3120 ttcacccagt aacaaaaaaaatttggtttc tttactttat atttatgtag gtcacaaaaa 3180 aaaagtgatg cagttttgtgggtcggttgt ctccacacca cctccgcctc cagcagcaca 3240 caatcatctt cgtgtgttctcgacgattcc ttgtatgccg cggtcgtgaa tgcaccacat 3300 tcgacgcgca actacacaccacactcactt tcggtggtat tactacacgt catcgttgtt 3360 cgtagtctcc cgctctttcgtccccactca ctcctcatta ttccccttgg tgtattgatt 3420 ttttttaaat ggtacaccactcctgacgtt tctaccttct tgttttccgt ccatttagat 3480 tttatctgga aatttttttaaaattttagg ccagagagtt ctagttcttg ttctaaaagt 3540 ctaggtcaga catacattttctatttctca tcaaaaaaaa agttgataaa gaaaactggt 3600 tattcagaaa gagtgtgtctcgttgaaatt gattcaaaaa aaaattccca cccctcgctt 3660 gtttctcaaa atatgagatcaacggatttt ttccttctcg attcaatttt ttgctgcgct 3720 ctgtctgcca aagtgtgtgtgtccgagcaa aagatgagag aatttacaaa cagaaatgaa 3780 aaaaagttgg ccaaataatgaagttttatc cgagattgat gggaaagata ttaatgttct 3840 ttacggtttg gaggggagagagagatagat tttcgcatca aactccgcct tttacatgtc 3900 ttttagaatc taaaatagatttttctcatc atttttaata gaaaatcgag aaattacagt 3960 aatttcgcaa ttttcttgccaaaaatacac gaaatttgtg ggtctcgcca cgatctcggt 4020 cttagtggtt catttggtttaaaagtttat aaaatttcaa attctagtgt ttaatttccg 4080 cataattgga cctaaaatgggtttttgtca tcattttcaa caagaaatcg tgaaaatcct 4140 gttgtttcgc aattttcttttcaaaaatac acgaaatata tggtaatttc ccgaaatatt 4200 gagggtctcg ccacgatttcagtcacagtg gccaggattt atcacgaaaa aagttcgcct 4260 agtctcacat ttccggaaaaccgaatctaa attagttttt tgtcatcatt ttgaacaaaa 4320 aatcgagaca tccctatagtttcgcaattt tcgtcgcttt tctctccaaa aatgacagtc 4380 tagaattaaa attcgctggaactgggacca tgatatcttt tctccccgtt tttcatttta 4440 ttttttatta cactggattgactaaaggtc accaccaccg ccagtgtgtg ccatatcaca 4500 cacacacaca cacacaatgtcgagatttta tgtgttatcc ctgcttgatt tcgttccgtt 4560 gtctctctct ctctattcatcttttgagcc gagaagctcc agagaatgga gcacacagga 4620 tcccggcgcg cgatgtcgtcgggagatggc gccgcctggg aagccgccga gagatatcag 4680 ggaagatcgt ctgatttctcctcggatgcc acctcatctc tcgagtttct ccgcctgtta 4740 ctccctgccg aacctgatatttcccgttgt cgtaaagaga tgtttttatt ttactttaca 4800 ccgggtcctc tctctctgccagcacagctc agtgttggct gtgtgctcgg gctcctgcca 4860 ccggcggcct catcttcttcttcttcttct ctcctgctct cgcttatcac ttcttcattc 4920 attcttattc cttttcatcatcaaactagc atttcttact ttatttattt ttttcaattt 4980 tcaattttca gataaaaccaaactacttgg gttacagccg tcaaca 5026 4 2915 DNA Caenorhabditis elegans 4ctgcagagca aaaaaatact gcttttcctt gcaaaattcg gtgctttctt caaagagaaa 60cttttgaagt cggcgcgagc atttccttct ttgacttctc tctttccgcc aaaaagccta 120gcatttttat tgataatttg attacacaca ctcagagttc ttcgacatga taaagtgttt 180cattggcact cgccctaaca gtacatgaca agggcggatt attatcgatc gatattgaag 240acaaactcca aatgtgtgct cattttggag ccccgtgtgg ggcagctgct ctcaatatat 300tactagggag acgaggaggg ggaccttatc gaacgtcgca tgagccattc tttcttcttt 360atgcactctc ttcactctct cacacattaa tcgattcata gactcccata ttccttgatg 420aaggtgtggg tttttagctt tttttcccga tttgtaaaag gaagaggctg acgatgttag 480gaaaaagaga acggagccga aaaaacatcc gtagtaagtc ttccttttaa gccgacactt 540tttagacagc attcgccgct agttttgaag tttaaatttt aaaaaataaa aattagtttc 600aatttttttt aattactaaa taggcaaaag ttttttcaag aactctagaa aaactagctt 660aattcatggg tactagaaaa attcttgttt taaatttaat atttatctta agatgtaatt 720acgagaagct tttttgaaaa ttctcaatta aaagaatttg ccgatttaga ataaaagtct 780tcagaaatga gtaaaagctc aaattagaag tttgttttta aaggaaaaac acgaaaaaag 840aacactattt atcttttcct ccccgcgtaa aattagttgt tgtgataata gtgatccgct 900gtctatttgc actcggctct tcacaccgtg cttcctctca cttgacccaa caggaaaaaa 960aaacatcacg tctgagacgg tgaattgcct tatcaagagc gtcgtctctt tcacccagta 1020acaaaaaaaa tttggtttct ttactttata tttatgtagg tcacaaaaaa aaagtgatgc 1080agttttgtgg gtcggttgtc tccacaccac ctccgcctcc agcagcacac aatcatcttc 1140gtgtgttctc gacgattcct tgtatgccgc ggtcgtgaat gcaccacatt cgacgcgcaa 1200ctacacacca cactcacttt cggtggtatt actacacgtc atcgttgttc gtagtctccc 1260gctctttcgt ccccactcac tcctcattat tccccttggt gtattgattt tttttaaatg 1320gtacaccact cctgacgttt ctaccttctt gttttccgtc catttagatt ttatctggaa 1380atttttttaa aattttaggc cagagagttc tagttcttgt tctaaaagtc taggtcagac 1440atacattttc tatttctcat caaaaaaaaa gttgataaag aaaactggtt attcagaaag 1500agtgtgtctc gttgaaattg attcaaaaaa aaattcccac ccctcgcttg tttctcaaaa 1560tatgagatca acggattttt tccttctcga ttcaattttt tgctgcgctc tgtctgccaa 1620agtgtgtgtg tccgagcaaa agatgagaga atttacaaac agaaatgaaa aaaagttggc 1680caaataatga agttttatcc gagattgatg ggaaagatat taatgttctt tacggtttgg 1740aggggagaga gagatagatt ttcgcatcaa actccgcctt ttacatgtct tttagaatct 1800aaaatagatt tttctcatca tttttaatag aaaatcgaga aattacagta atttcgcaat 1860tttcttgcca aaaatacacg aaatttgtgg gtctcgccac gatctcggtc ttagtggttc 1920atttggttta aaagtttata aaatttcaaa ttctagtgtt taatttccgc ataattggac 1980ctaaaatggg tttttgtcat cattttcaac aagaaatcgt gaaaatcctg ttgtttcgca 2040attttctttt caaaaataca cgaaatatat ggtaatttcc cgaaatattg agggtctcgc 2100cacgatttca gtcacagtgg ccaggattta tcacgaaaaa agttcgccta gtctcacatt 2160tccggaaaac cgaatctaaa ttagtttttt gtcatcattt tgaacaaaaa atcgagacat 2220ccctatagtt tcgcaatttt cgtcgctttt ctctccaaaa atgacagtct agaattaaaa 2280ttcgctggaa ctgggaccat gatatctttt ctccccgttt ttcattttat tttttattac 2340actggattga ctaaaggtca ccaccaccgc cagtgtgtgc catatcacac acacacacac 2400acacaatgtc gagattttat gtgttatccc tgcttgattt cgttccgttg tctctctctc 2460tctattcatc ttttgagccg agaagctcca gagaatggag cacacaggat cccggcgcgc 2520gatgtcgtcg ggagatggcg ccgcctggga agccgccgag agatatcagg gaagatcgtc 2580tgatttctcc tcggatgcca cctcatctct cgagtttctc cgcctgttac tccctgccga 2640acctgatatt tcccgttgtc gtaaagagat gtttttattt tactttacac cgggtcctct 2700ctctctgcca gcacagctca gtgttggctg tgtgctcggg ctcctgccac cggcggcctc 2760atcttcttct tcttcttctc tcctgctctc gcttatcact tcttcattca ttcttattcc 2820ttttcatcat caaactagca tttcttactt tatttatttt tttcaatttt caattttcag 2880ataaaaccaa actacttggg ttacagccgt caaca 2915 5 6612 DNA Caenorhabditiselegans 5 tcgactctag ttttgaaatc caaaaaaaaa acaaagttca ataaaatgttacccaattgt 60 gcgatttttg ctttaaaaat acggtacccg gtctcgatgc ggcaattgtttggtaaatgt 120 aaaagggtgt gcgcctttaa agagtactgt aatttcaatc ttccgacactgctgaatttt 180 tattgacttt ttgttcatta attttatata tgatttattg gtatgttaaaaaaacaccca 240 ttttcaaatc tattaaaatt ccacaacaac aaaagttcga gattacagtactttttagag 300 gcgcacatcc tttttgggat actaaacaat tgtcgcgtcg agaccaggtaccatatttcc 360 aaaacacaat ttcgcgtgta aataaaaaat atcaacataa taatttccatttttcgaaat 420 ttaaagttaa tcactttttg gtttagatta tgatttcaca cgtttttttccttctagttc 480 tctttttttt gttatttgcc tgaaaaatgg tctgaaaact taggcaatcagcaatgtgtc 540 acataatttc tcccagagaa atccctttca acaaaatctc ccggattgacctgtgtgctc 600 gaccttgata aattggttgg cagctctctg gcttatcttt tgagaggaaaaagatccaac 660 aaatttttat ctcccttatc cctttttctc ttcatcacta ccaataataatagttttttt 720 tttcgtcgcg gaagcaaaat ggcgaacaag tgttggaata agagtactccagggatttaa 780 gggctgaaag ccagtgattt atgagctcca atttttcaga tgttttttcctccatcgcgt 840 atttgtctaa acattcgatt ttcttcctgc ttcccaactt ttcaaatcgaaataaaagag 900 catctgtcgc tttttatcga tgtgcttctg tgagactaaa gaactactcgttttcactcg 960 ttctctctct ctcaactatc aaagttttgt tgattgcgtg tgtcagcttccttcttttta 1020 ttatcatctt ttcattggag gaaaaaaata acttctgaag agcaaaagaactaacttcgg 1080 ggaatacaga gaaaattcct gtaaaaatct ggaaattttt tcgcttaactcgaaatattt 1140 agtttttcac tgtgatttct gggaaaaatc aagaaatatt tgcctaaaacacgagttttc 1200 acatgaaaaa tgaattattt attgattttt tatggagatt acaaaaaagacacacgtgaa 1260 actactgcta ccgtagttgt gtaaacgtag tgttctctat tttagacctgtttaatgtat 1320 ttttttgcag ttgaaaattt ttaaaaatat tttagttatt tttaaaaatatttaatttac 1380 aaaataatta gcctgaaccc atgaaaagat acgttatatt taatttttaccgtaagactt 1440 tcaagatcgt tgcgagaccc ggcgcctagg tcaaagagcc tccctttaaacccatcaaca 1500 cgttttgcct ttttcatcga ttttttgcag ttcttttctt ctttccaactgatttttctt 1560 catttttaaa gtttttttcc tcatttttcc catttgaaat tatttaaacacgtgcaacca 1620 gctggtaaca tgtgtcacat gccgttatct aacttcaaaa cagtacatttccgatcacac 1680 gtcccccgcg ccgagtttta tagtttcatt aataactttt cggtttttgataatactaat 1740 tgagttttat taattgtttc catattcatc tagcactttg acctgtccttcttcgaattc 1800 tcaaatattt gcactctggg tttaggtgtg aaaagaattg tcgtcattaagcggggcatc 1860 cggggcaccg aaaaaagccc tccgatttta acgaatttga gataaagttggagagagagc 1920 ccagtgtttg cttgcccaag atatatatct tggatttatc aattactgtttgtcaacctg 1980 tcgccggcgc cccctttttg ctcttgctcc cacgccccga gattgaatttcaattttatt 2040 tcgaagtaag tctcttgatt gtttcgaaaa tccgatgaca gttttcattacttttttgtc 2100 tgttgatttt gtagggaaac attgaaattt ttctgatctt tctttgatcttatgattttt 2160 catttattcc aattaaaaaa aattagcgca ttcagaacca gagtgaagcttgagatgttg 2220 taggtttatc aaaagatcaa aatctcgaat tccttcgaaa tgtttttagttttcgacttc 2280 cgtgtgattt ctagcgatcc tgacagagat cactgaattt taatgttatcgagattgttg 2340 tgtaggctcc atctcctctc tgaagcttct gattttgccg aaagtctagttacttgccga 2400 ctgctgacac taggatatcc cactaccgta cccattgttg gatccgtactctgctgcgac 2460 ttcttctctg tttcacgtga acctccggga tcgtcggtaa gccccgcccgttatctgtgc 2520 caacttgtct tcgtgccctc gagcgacgag ctcattcaat cacgccacgacctccgtctg 2580 gacagatgct ctcattgtct ctgcgtctcc aagtattcgt cacactatctcatgcattct 2640 attcaaaacg cgagagaaag cgcgggaacg agagagagtt cagacagatcgaacttgttt 2700 ttatcccccc ccccctcgtc cggctgcaga gcaaaaaaat actgcttttccttgcaaaat 2760 tcggtgcttt cttcaaagag aaacttttga agtcggcgcg agcatttccttctttgactt 2820 ctctctttcc gccaaaaagc ctagcatttt tattgataat ttgattacacacactcagag 2880 ttcttcgaca tgataaagtg tttcattggc actcgcccta acagtacatgacaagggcgg 2940 attattatcg atcgatattg aagacaaact ccaaatgtgt gctcattttggagccccgtg 3000 tggggcagct gctctcaata tattactagg gagacgagga gggggaccttatcgaacgtc 3060 gcatgagcca ttctttcttc tttatgcact ctcttcactc tctcacacattaatcgattc 3120 atagactccc atattccttg atgaaggtgt gggtttttag ctttttttcccgatttgtaa 3180 aaggaagagg ctgacgatgt taggaaaaag agaacggagc cgaaaaaacatccgtagtaa 3240 gtcttccttt taagccgaca ctttttagac agcattcgcc gctagttttgaagtttaaat 3300 tttaaaaaat aaaaattagt ttcaattttt tttaattact aaataggcaaaagttttttc 3360 aagaactcta gaaaaactag cttaattcat gggtactaga aaaattcttgttttaaattt 3420 aatatttatc ttaagatgta attacgagaa gcttttttga aaattctcaattaaaagaat 3480 ttgccgattt agaataaaag tcttcagaaa tgagtaaaag ctcaaattagaagtttgttt 3540 ttaaaggaaa aacacgaaaa aagaacacta tttatctttt cctccccgcgtaaaattagt 3600 tgttgtgata atagtgatcc gctgtctatt tgcactcggc tcttcacaccgtgcttcctc 3660 tcacttgacc caacaggaaa aaaaaacatc acgtctgaga cggtgaattgccttatcaag 3720 agcgtcgtct ctttcaccca gtaacaaaaa aaatttggtt tctttactttatatttatgt 3780 aggtcacaaa aaaaaagtga tgcagttttg tgggtcggtt gtctccacaccacctccgcc 3840 tccagcagca cacaatcatc ttcgtgtgtt ctcgacgatt ccttgtatgccgcggtcgtg 3900 aatgcaccac attcgacgcg caactacaca ccacactcac tttcggtggtattactacac 3960 gtcatcgttg ttcgtagtct cccgctcttt cgtccccact cactcctcattattcccctt 4020 ggtgtattga ttttttttaa atggtacacc actcctgacg tttctaccttcttgttttcc 4080 gtccatttag attttatctg gaaatttttt taaaatttta ggccagagagttctagttct 4140 tgttctaaaa gtctaggtca gacatacatt ttctatttct catcaaaaaaaaagttgata 4200 aagaaaactg gttattcaga aagagtgtgt ctcgttgaaa ttgattcaaaaaaaaattcc 4260 cacccctcgc ttgtttctca aaatatgaga tcaacggatt ttttccttctcgattcaatt 4320 ttttgctgcg ctctgtctgc caaagtgtgt gtgtccgagc aaaagatgagagaatttaca 4380 aacagaaatg aaaaaaagtt ggccaaataa tgaagtttta tccgagattgatgggaaaga 4440 tattaatgtt ctttacggtt tggaggggag agagagatag attttcgcatcaaactccgc 4500 cttttacatg tcttttagaa tctaaaatag atttttctca tcatttttaatagaaaatcg 4560 agaaattaca gtaatttcgc aattttcttg ccaaaaatac acgaaatttgtgggtctcgc 4620 cacgatctcg gtcttagtgg ttcatttggt ttaaaagttt ataaaatttcaaattctagt 4680 gtttaatttc cgcataattg gacctaaaat gggtttttgt catcattttcaacaagaaat 4740 cgtgaaaatc ctgttgtttc gcaattttct tttcaaaaat acacgaaatatatggtaatt 4800 tcccgaaata ttgagggtct cgccacgatt tcagtcacag tggccaggatttatcacgaa 4860 aaaagttcgc ctagtctcac atttccggaa aaccgaatct aaattagttttttgtcatca 4920 ttttgaacaa aaaatcgaga catccctata gtttcgcaat tttcgtcgcttttctctcca 4980 aaaatgacag tctagaatta aaattcgctg gaactgggac catgatatcttttctccccg 5040 tttttcattt tattttttat tacactggat tgactaaagg tcaccaccaccgccagtgtg 5100 tgccatatca cacacacaca cacacacaat gtcgagattt tatgtgttatccctgcttga 5160 tttcgttccg ttgtctctct ctctctattc atcttttgag ccgagaagctccagagaatg 5220 gagcacacag gatcccggcg cgcgatgtcg tcgggagatg gcgccgcctgggaagccgcc 5280 gagagatatc agggaagatc gtctgatttc tcctcggatg ccacctcatctctcgagttt 5340 ctccgcctgt tactccctgc cgaacctgat atttcccgtt gtcgtaaagagatgttttta 5400 ttttacttta caccgggtcc tctctctctg ccagcacagc tcagtgttggctgtgtgctc 5460 gggctcctgc caccggcggc ctcatcttct tcttcttctt ctctcctgctctcgcttatc 5520 acttcttcat tcattcttat tccttttcat catcaaacta gcatttcttactttatttat 5580 ttttttcaat tttcaatttt cagataaaac caaactactt gggttacagccgtcaacatg 5640 gaggacgcgc atgccaaaga cgccaatgag gtacttttat agtttttaaattttagtttt 5700 taatacaatt tattttccag gtgtgcaaat tcttcggaac gggtccggagggattgactc 5760 cacagcaagt tgaaacattg aggaacaaat atggagaaaa tggttggttttttacatgga 5820 tttctcatta aaaattgaat tttttccaga aatgcccgcc gaagagggaaaatcactgtg 5880 ggagctgatt ctcgagcaat tcgacgatct tctcgtcaag attctcctcctcgccgccat 5940 catctcgttt gtgctcgccc ttttcgaaga gcacgaagat cagacagaagcagtgacggc 6000 gttcgtcgaa ccgttcgtca tccttctcat tcttattgcc aacgcgaccgtcggagtgtg 6060 gcaggtagga acaacacaga caggcgcacg cgctgaaaga aaataagaagaagaagaaaa 6120 agcacagttg ttttctgtgt ttttgtagat caaaagaaag gaactaggagtgattgcaca 6180 gagagagaga gagagaaata atgtcttttt gacttgtttt tgttggtgagagagataggg 6240 aaaaagagtc cctaaagaaa aaatagtgta acgggcggtc cggaagaaatgctctttgcg 6300 ccgaaaagtt tttgaaaaaa gaagaaaatg atgaaggaaa ggcgtgcgtcatgagcttcg 6360 catttacgta cgcaaaaagt gagggatatg tgaaaaagat attgggtgatagaatagttg 6420 atggattggg ctgcactatt tgcctcaatt tgccacaaat ttccatctaatttgtcataa 6480 ttttccagga acgaaatgct gaatcggcca tcgaagcgct caaggaatacgaaccagaaa 6540 tggccaaggt catccgatcc ggacaccacg gaattcagat ggttcgcgctaaggaactcg 6600 tgccaggaga tc 6612 6 3180 DNA Caenorhabditis elegans 6atggaggacg cgcatgccaa agacgccaat gaggtgtgca aattcttcgg aacgggtccg 60gagggattga ctccacagca agttgaaaca ttgaggaaca aatatggaga aaatgaaatg 120cccgccgaag agggaaaatc actgtgggag ctgattctcg agcaattcga cgatcttctc 180gtcaagattc tcctcctcgc cgccatcatc tcgtttgtgc tcgccctttt cgaagagcac 240gaagatcaga cagaagcagt gacggcgttc gtcgaaccgt tcgtcatcct tctcattctt 300attgccaacg cgaccgtcgg agtgtggcag gaacgaaatg ctgaatcggc catcgaagcg 360ctcaaggaat acgaaccaga aatggccaag gtcatccgat ccggacacca cggaattcag 420atggttcgcg ctaaggaact cgtgccagga gatcttgtcg aagtttcagt cggagacaag 480atcccagccg atctccgtct tgtgaagatc tactccacca ccatccgtat cgatcagtcc 540atcctcaccg gagaatctgt gtctgttatc aagcacaccg actctgtgcc agatccacgc 600gctgttaacc aggacaagaa gaattgtctg ttctcgggaa ccaatgtcgc atctggaaag 660gctcgtggaa tcgtcttcgg aaccggattg accactgaaa tcggaaagat ccgtaccgaa 720atggctgaga ccgagaatga gaagacacca cttcaacaga agttggacga attcggagag 780caactttcca aggttatctc tgttatttgc gttgctgttt gggctatcaa cattggacat 840ttcaacgatc cagctcacgg tggatcatgg gttaagggag caatctacta cttcaaaatc 900gccgttgctc ttgccgtcgc tgctattcca gaaggacttc cagctgtcat caccacgtgc 960cttgccctcg gaactcgccg tatggccaag aagaacgcta ttgtaagatc ccttccatcc 1020gtcgaaactc ttggatgcac atctgttatc tgctctgaca agactggaac tctcaccacc 1080aaccagatgt ctgtgtcaaa gatgttcatc gctggacaag cttctggaga caacatcaac 1140ttcaccgagt tcgccatctc cggatccacc tacgagccag tcggaaaggt ttccaccaat 1200ggacgtgaaa tcaacccagc tgctggagaa ttcgaatcac tcaccgagtt ggccatgatc 1260tgcgctatgt gcaatgattc atctgttgat tacaatgaga ccaagaagat ctacgagaaa 1320gtcggagaag ccactgaaac tgctcttatc gttcttgctg agaagatgaa tgttttcgga 1380acctcgaaag ccggactttc accaaaggag ctcggaggag tttgcaaccg tgtcatccaa 1440caaaaatgga agaaggagtt cacactcgag ttctcccgtg atcgtaaatc catgtccgcc 1500tactgcttcc cagcttccgg aggatctgga gccaagatgt tcgtgaaggg agccccagaa 1560ggagttctcg gaagatgcac ccacgtcaga gttaacggac aaaaggttcc actcacctct 1620gccatgactc agaagattgt tgaccaatgc gtgcaatacg gaaccggaag agataccctt 1680cgttgtcttg ccctcggaac catcgatacc ccagtcagcg ttagcaacat gaacctcgaa 1740gactctaccc aattcgtcaa atacgaacaa gacatcacat ttgtcggagt cgtcggaatg 1800cttgaccccc caagaactga agtttcggac tcgatcaagg cttgtaacca cgctggaatc 1860cgtgtcatca tgatcaccgg agacaacaag aacaccgctg aggctatcgg aagaagaatc 1920ggactcttcg gagagaacga ggataccact ggaaaagctt acactggacg tgaatttgac 1980gatcttccac cagagcaaca atctgaagcc tgccgcagag ctaagctttt cgcccgtgtc 2040gagccatctc acaagtccaa gattgtcgat atccttcaat cccagggaga gattactgct 2100atgaccggag acggagtcaa cgacgctcca gctttgaaga aggccgaaat cggaatttct 2160atgggatcag gaactgctgt cgccaagtct gcatctgaaa tggttcttgc tgacgataac 2220ttcgcatcca ttgtgtctgc tgtcgaagaa ggacgtgcta tttacaacaa catgaaacaa 2280ttcatcagat atctcatctc atctaacgtc ggagaagtcg tctccatctt catggtcgcc 2340gcactcggaa ttccagaggc tctcattcca gttcaacttc tctgggttaa cttggtcact 2400gacggtcttc cagccactgc tctcggattc aatccaccag atcttgacat tatggacaga 2460catccacgtt cagccaacga tggactcatc tctggatggc tcttcttcag atatcttgct 2520gtcggaacct acgtcggagt tgccaccgtc ggagcctcaa tgtggtggtt cttgttgtac 2580gaggagggac cacagatcac ctactaccag ctcactcact ggatgagatg tgaaatcgag 2640ccagacaact ttgccgatct tgactgcgcc gtattcgagg acaatcaccc gaacgccatg 2700gctctgtccg tgcttgtcac cattgagatg ctcaacgcca tcaactcact ttccgagaat 2760caatcgcttt tagtgatgcc accatggaag aacatctggc tgatggccgc catttccctt 2820tcgatgtctc ttcactttgt cattctctac gttgacatca tggccaccat cttccagatc 2880acccctctca actgggtcga atggatcgcc gtgttgaaga tctcactgcc agtgctcctt 2940ctcgatgaaa ttctcaagtt catcgccaga aactacatcg acggtaagcc ggagacggtc 3000ggcgcgaagg cacgtagtgc catctcgctg ctcgcctggg tgtctgtgac gctcgcctac 3060tttgcgtgga tgttgggccc gtacgccgag ctcattaacc atgcgctcgt cggtccatct 3120gtcgatccgt cgaaattcga cgcggttgtc acgcccgaca agttacataa cgaattgtga 3180 72994 DNA Sus sp. 7 atggagaacg cgcacacaaa gacggtggag gaggtgctgggccacttcgg cgtcaacgag 60 agcacggggc tgagcctgga gcaggtcaag aagctcaaggagagatgggg ctccaacgag 120 ttaccggctg aagaagggaa aaccttgctg gaacttgtgattgagcagtt tgaagactta 180 ctcgttagaa ttttattgtt ggcagcatgt atatcttttgttttggcttg gtttgaagaa 240 ggcgaagaaa caattacagc ctttgtagaa ccctttgtaattttacttat attagtagcc 300 aatgcaattg tgggtgtatg gcaggaaagg aatgcagaaaatgccatcga agcccttaag 360 gagtatgagc ctgaaatggg caaagtgtat cgacaggacaggaagagtgt acaacgaatt 420 aaagctaaag acatagttcc tggtgatatt gtagaaattgctgttggtga caaagttcct 480 gctgatataa gattaacgtc catcaaatct actactctaagagttgacca gtcaattctc 540 acaggtgagt ctgtctctgt catcaagcac accgaccctgtccctgaccc acgggctgtc 600 aaccaagata agaagaacat gctcttttct ggtacaaacatagcagctgg caaagccatg 660 ggagtggtgg tggcaactgg agttaacact gaaattggcaagatccggga tgaaatggta 720 gcaacggaac aggagagaac acccctccag cagaaactagatgagtttgg ggaacagctt 780 tccaaagtca tctcccttat ttgcattgca gtctggatcataaacattgg gcacttcaat 840 gacccggttc atggaggctc ctggatcaga ggtgctatttattactttaa aattgcagtg 900 gccctggctg tagcagccat tcctgaaggc ctgcctgctgtcattaccac ctgcctggct 960 cttggaactc gtagaatggc aaagaaaaat gccattgttcgaagtctccc ttctgtggaa 1020 acccttggtt gcacttccgt tatctgctca gacaagactggtacacttac aacaaaccag 1080 atgtcagtct gcaggatgtt cattctggac aaagttgaaggtgatacttg ttccctgaat 1140 gagtttacca taactggatc aacatatgct cctattggagaagtccataa agatgataaa 1200 ccagtaaagt gtcatcaata tgatggtctt gtggaattggcaacaatttg tgctctctgt 1260 aatgactctg ctttggatta caatgaggca aagggtgtgtatgaaaaagt tggagaagct 1320 acagagactg ctctcacttg cctggtagag aagatgaatgtctttgatac tgagttaaag 1380 ggtctttcta aaatagaacg agcaaatgcc tgcaactcggtcattaaaca attgatgaaa 1440 aaggaattta ctctagagtt ttcacgtgat agaaaatcaatgtcagttta ttgtacacca 1500 aacaaaccaa gccggacatc gatgagcaaa atgtttgtgaagggtgctcc cgaaggtgtc 1560 attgacaggt gtacccacat tcgagttgga agtactaaagtccccatgac tcctggcgtc 1620 aaacagaaga tcatgtctgt cattcgggaa tggggcagtggcagcgacac actgcgatgc 1680 ctggctctgg ccactcatga caacccgatg agaagagaagaaatgaacct tgaggattct 1740 gccaacttta ttaaatacga gaccaatctg actttcgttggctgtgtggg catgctggac 1800 cctccaagaa tcgaagtggc ctcctctgtg aagctgtgccggcaggcagg catccgggtc 1860 attatgatca caggcgacaa caagggtacc gctgtggccatctgccgtcg cattggcatc 1920 tttgggcagg acgaggatgt gacgtcaaag gcttttacaggtcgggagtt tgatgagctc 1980 aatccttcag cccagagaga agcctgcctg aatgcccgctgtttcgctcg agttgaacct 2040 tcccacaagt ctaaaattgt agaatttctt cagtcttttgatgagattac agctatgact 2100 ggggacggtg tgaatgatgc tcctgctctg aagaagtctgagatcggcat tgccatgggc 2160 tctggcaccg cggtggctaa aactgcctcc gagatggtcctggctgatga caacttctcc 2220 accattgtgg ctgctgtgga ggagggacgg gcaatatacaacaacatgaa gcagttcatt 2280 cgctacctca tctcgtccaa cgtgggagaa gttgtctgtattttcctgac agcagccctt 2340 ggatttcctg aggctttaat tcctgtccag ctgctctgggtcaatctggt gacagatggc 2400 ctgcctgcca ctgcactggg gttcaatcct cctgatctggacattatgaa caaaccaccc 2460 cggaacccaa aggaaccact gatcagtggg tggctctttttccgctacct ggctattggc 2520 tgttacgttg gtgctgctac tgtgggtgct gctgcgtggtggttcattgc tgccgatggt 2580 ggtccgagag tgaccttcta ccagctgagt catttcctacagtgtaaaga ggacaaccca 2640 gactttgagg gagtggattg tgcagtcttt gaatccccttacccaatgac aatggcgctg 2700 tctgttctag tcaccataga gatgtgtaac gccctcaacagtttgtcgga aaaccagtcc 2760 ctgctaagga tgccaccttg ggagaacatt tggctcgtgggctccatctg cctgtccatg 2820 tcactccact tcctaatcct ctatgtggaa cccctgccacttatcttcca gatcacaccg 2880 ctgaatttga cccagtggct gatggtgctg aaaatctccttgcctgtgat tctaatggat 2940 gagaccctca agtttgtggc ccgcaactac ctggaacctgcaatactgga gtaa 2994 8 2994 DNA Homo sapiens 8 atggagaacg cgcacaccaagacggtggag gaggtgctgg gccacttcgg cgtcaacgag 60 agtacggggc tgagcctggaacaggtcaag aagcttaagg agagatgggg ctccaacgag 120 ttaccggctg aagaaggaaaaaccttgctg gaacttgtga ttgagcagtt tgaagacttg 180 ctagttagga ttttattactggcagcatgt atatcttttg ttttggcttg gtttgaagaa 240 ggtgaagaaa caattacagcctttgtagaa ccttttgtaa ttttactcat attagtagcc 300 aatgcaattg tgggtgtatggcaggaaaga aatgctgaaa atgccatcga agcccttaag 360 gaatatgagc ctgaaatgggcaaagtgtat cgacaggaca gaaagagtgt gcagcggatt 420 aaagctaaag acatagttcctggtgatatt gtagaaattg ctgttggtga caaagttcct 480 gctgatataa ggttaacttccatcaaatct accacactaa gagttgacca gtcaattctc 540 acaggtgaat ctgtctctgtcatcaagcac actgatcccg tccctgaccc acgagctgtc 600 aaccaagata aaaagaacatgctgttttct ggtacaaaca ttgctgctgg gaaagctatg 660 ggagtggtgg tagcaactggagttaacacc gaaattggca agatccggga tgaaatggtg 720 gcaacagaac aggagagaacaccccttcag caaaaactag atgaatttgg ggaacagctt 780 tccaaagtca tctcccttatttgcattgca gtctggatca taaatattgg gcacttcaat 840 gacccggttc atggagggtcctggatcaga ggtgctattt actactttaa aattgcagtg 900 gccctggctg tagcagccattcctgaaggt ctgcctgcag tcatcaccac ctgcctggct 960 cttggaactc gcagaatggcaaagaaaaat gccattgttc gaagcctccc gtctgtggaa 1020 acccttggtt gtacttctgttatctgctca gacaagactg gtacacttac aacaaaccag 1080 atgtcagtct gcaggatgttcattctggac agagtggaag gtgatacttg ttcccttaat 1140 gagtttacca taactggatcaacttatgca cctattggag aagtgcataa agatgataaa 1200 ccagtgaatt gtcaccagtatgatggtctg gtagaattag caacaatttg tgctctttgt 1260 aatgactctg ctttggattacaatgaggca aagggtgtgt atgaaaaagt tggagaagct 1320 acagagactg ctctcacttgcctagtagag aagatgaatg tatttgatac cgaattgaag 1380 ggtctttcta aaatagaacgtgcaaatgcc tgcaactcag tcattaaaca gctgatgaaa 1440 aaggaattca ctctagagttttcacgtgac agaaagtcaa tgtcggttta ctgtacacca 1500 aataaaccaa gcaggacatcaatgagcaag atgtttgtga agggtgctcc tgaaggtgtc 1560 attgacaggt gcacccacattcgagttgga agtactaagg ttcctatgac ctctggagtc 1620 aaacagaaga tcatgtctgtcattcgagag tggggtagtg gcagcgacac actgcgatgc 1680 ctggccctgg ccactcatgacaacccactg agaagagaag aaatgcacct tgaggactct 1740 gccaacttta ttaaatatgagaccaatctg accttcgttg gctgcgtggg catgctggat 1800 cctccgagaa tcgaggtggcctcctccgtg aagctgtgcc ggcaagcagg catccgggtc 1860 atcatgatca ctggggacaacaagggcact gctgtggcca tctgtcgccg catcggcatc 1920 ttcgggcagg atgaggacgtgacgtcaaaa gctttcacag gccgggagtt tgatgaactc 1980 aacccctccg cccagcgagacgcctgcctg aacgcccgct gttttgctcg agttgaaccc 2040 tcccacaagt ctaaaatcgtagaatttctt cagtcttttg atgagattac agctatgact 2100 ggcgatggcg tgaacgatgctcctgctctg aagaaagccg agattggcat tgctatgggc 2160 tctggcactg cggtggctaaaaccgcctct gagatggtcc tggcggatga caacttctcc 2220 accattgtgg ctgccgttgaggaggggcgg gcaatctaca acaacatgaa acagttcatc 2280 cgctacctca tctcgtccaacgtcggggaa gttgtctgta ttttcctgac agcagccctt 2340 ggatttcccg aggctttgattcctgttcag ctgctctggg tcaatctggt gacagatggc 2400 ctgcctgcca ctgcactggggttcaaccct cctgatctgg acatcatgaa taaacctccc 2460 cggaacccaa aggaaccattgatcagcggg tggctctttt tccgttactt ggctattggc 2520 tgttacgtcg gcgctgctaccgtgggtgct gctgcatggt ggttcattgc tgctgacggt 2580 ggtccaagag tgtccttctaccagctgagt catttcctac agtgtaaaga ggacaacccg 2640 gactttgaag gcgtggattgtgcaatcttt gaatccccat acccgatgac aatggcgctc 2700 tctgttctag taactatagaaatgtgtaac gccctcaaca gcttgtccga aaaccagtcc 2760 ttgctgagga tgcccccctgggagaacatc tggctcgtgg gctccatctg cctgtccatg 2820 tcactccact tcctgatcctctatgtcgaa cccttgccac tcatcttcca gatcacaccg 2880 ctgaacgtga cccagtggctgatggtgctg aaaatctcct tgcccgtgat tctcatggat 2940 gagacgctca agtttgtggcccgcaactac ctggaacctg caatactgga gtaa 2994 9 159 DNA Sus sp. 9atggataaag tccaatacct cactcgctct gctattagaa gagcttcaac cattgaaatg 60cctcaacaag cacgtcaaaa ccttcagaac ctatttatca atttctgtct catcttaata 120tgcctcttgc tgatttgcat catcgtgatg cttctctga 159 10 837 DNA Caenorhabditiselegans 10 aaagtgaata atcgaccaaa taataactca ctttggtatt tattcctgtcttataatgtt 60 atgtatgaat taaattcata tgcatatggc tcactctgac aaaaaaaaataatcttccag 120 atcaatattg actaccgatg cgggtggtct tttgctttga attctgctgaactttacacc 180 ccgaacagca atgtgtgctt cagctaaaaa aaagtaagtg tgttaatcagtccccccgat 240 tcttcatttt ttgcccctct ctcccgtttc gtcggcaaaa gaagagaaaataaagataag 300 tctcaagata ggttggtaat cgctaaagtg gttgtgtgga taagagtagcaaaatggcag 360 gaagagcact ttgcgcgcac acactgtact cattgttctg gataaaattctctcgttgtt 420 tgccgtcgga tgtctgcctc tctgccattg agccggcttc ttcactatctttagttaacc 480 taaaatgccg tttcttttct cgtatcccac tatccgttga ggttctctgctctcttcgct 540 cccttaccgc cagcgagcaa ctatccgtgg gggcgccttg ctcggaagatgggggggaag 600 aaagaagatt tttgctattt gcacttgaga aagagacttt tcctgcgtcgatggttagag 660 aacagtgtgc agacactttt cagctaccta gatacatgga tatccccgcctcccaatcca 720 cccacccagg gaaaaagaag ggctcgccga aaaatcaaag ttatctccaggctcgcgcat 780 cccaccgagc ggttgacttc tctccaccac ttttcatttt aaccctcggggtacggg 837 11 2396 DNA Caenorhabditis elegans 11 agcttgggct gcaggtcggctataataagt tcttgaataa aataattttc ccgacaaaac 60 atgagtattt ctttcgaaaataaaagtgca ggctaattag agattattct gtaattaact 120 gcataatttg tcacgtgccatagttttaca ttccactacg tcatagttct taaaatacta 180 atctcctgaa aatagaagtaggtgaagaaa gtttaattat cagttctaaa atgacaattg 240 atctttggaa tatgttctgaaactaccgat cattgaacag atgctatttg aatgatatag 300 aattgtatat ttgcaatttctgaaacgcgt tcttaaaggc acacagatta attcaaaagg 360 gtctggccgc aaaaaggtttatggtggccg attttgagtt ttgtgtgtga ttgctttttc 420 acaatcagtg ttttcaggattatgtgatga actagatctt caagtttcgt tacatttcat 480 atgttttcgg aactcacgaagtacatattg ggtattgtgc tcaaaaaatt cagcaatcag 540 cttcgctccg ctgactttagaacccaaaaa aatagtatgg ccaaactgac tgtgttacga 600 tcatttcaat ttttcaatacatatttaaga tttctaagag taagaaggtc aaaaactgtt 660 ctggaataca tatatatttttcaggttaca attagtcaaa aagtgcactg aaatatacgt 720 tttaatttca cgaataacccaattagttca atgtattttt ggtcaaccaa cgttaaagtt 780 tggcttccaa ccaattatcatttctgatca accacaatgt tttttcttta tctgcaagtt 840 aattttttat ttttatccagatgtttggca tatttttcaa ttcttcacta gcgcccactt 900 cttgcacttc cggcgccctgaatctaatgc atctgttgca agaattgaaa gaccaatcaa 960 cacattgttt tcttcacgagatactgaaga aaatgaataa aaacagagaa aaagagccat 1020 gtgattagtg acaactgttgctaacagata ccatagcttg gacttggtac gtgatggcaa 1080 cgtatgggtc aacaaaaatgattgcagagg gggtgcaaaa cagtcaagtc gagaaaatat 1140 gaaaaacaga aaacaaagaacagaaaaatg ggtttgagag tcagtataat ttataaaaga 1200 aaaattgtac atagaaattaaccatttttg tagaagaagt tatttttcaa gcatcgttaa 1260 aaattattca aagcaccttatttcatattt aattttaaac atggttaaat gaacaacacg 1320 gtgcgcaatc aggaaaacttgaaatctgaa actgttgttg tgatcttctt cgcaactgtt 1380 cagatagcac tagtgtaatgttaagagtgc gcgaatataa tggaatataa tggatcacac 1440 ctcctgccat caggtaaacgtctctgttat cacatatttc caactattaa atttttacct 1500 tttacagttt tacatttttttgaaaaaagt aactttttgt cttcaaaatc cctgacgaaa 1560 atatcaaata ttttaatcgagactgcagag gaaccgattg atgatttgga aaatccagct 1620 ttacctgtgt aagaactgaaaagtttcata accctagggt attcccagtt acattcccca 1680 ctggctaaca atagcacccagtttttcatc acctttcttc aaatttctcg gcgatttgtt 1740 aaaaacaaaa tttgtgtcccttctctgata tctctatgtc tctaaacaca agttcatcgg 1800 aaaacgaagg agggtaggtgttggttgggc tcccgaagtg aaaatagaag agcaagaata 1860 gaatattaga gagagagtgcagagagggcg ggatagctcc cgggattccg ttttcttctt 1920 ctttatcttc aacgatgatgtgtgtgcgtg ttgtatagat tctgttgctc ccccacaact 1980 cgctccgaag gctcaatacaattcaattga tattggagga gagcctaccg gagtgggagg 2040 ataagaagaa acataagaagaagaagaaga agaagcatgc ttctggtttt tgatgctatg 2100 aaaacggcac aaaaagatgattgaggtccc ttttcaatac cttctctcat ctttcaaatc 2160 ccattgaaac ctaaaacttctcaccacgct ttaccattgt tctccaaaaa cttatagcaa 2220 tgtctataac ttttttatctctgaaaagca gtgttccatt tttctttttc ctattttatt 2280 tcaattgttt ctcacatttcgtttggattc tttgcttgtc aaccagcttc ttcttccact 2340 tttaccgtct aattttcagggcagggagcc atcaaaccca cgaccactag atccat 2396 12 45 DNA Caenorhabditiselegans 12 ccttctcgat ttcaaaatgt caactaaaca tatgcaacat atgtg 45 13 159DNA Artificial Sequence Description of Artificial SequenceHUMANIZED PIGPLB cDNA 13 atggagaaag tccaatacct cactcgctct gctattagaa gagcttcaaccattgaaatg 60 cctcaacaag cacgtcaaaa ccttcagaac ctatttatca atttctgtctcatcttaata 120 tgcctcttgc tgatttgcat catcgtgatg cttctctga 159 14 52 PRTSus sp. 14 Met Asp Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg AlaSer 1 5 10 15 Thr Ile Glu Met Pro Gln Gln Ala Arg Gln Asn Leu Gln AsnLeu Phe 20 25 30 Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile CysIle Ile 35 40 45 Val Met Leu Leu 50 15 52 PRT Homo sapiens 15 Met GluLys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser 1 5 10 15 ThrIle Glu Met Pro Gln Gln Ala Arg Gln Asn Leu Gln Asn Leu Phe 20 25 30 IleAsn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile 35 40 45 ValMet Leu Leu 50 16 2251 DNA Caenorhabditis elegans 16 gaacgaaatgctgaatcggc catcgaagcg ctcaaggaat acgaaccaga aatggccaag 60 gtcatccgatccggacacca cggaattcag atggttcgcg ctaaggaact cgtgccagga 120 gatcttgtcgaagtttcagg ttagcaaaaa cttttttttt taactttcaa attttaaacc 180 atatatttttcagtcggaga caagatccca gccgatctcc gtcttgtgaa gatctactcc 240 accaccatccgtatcgatca gtccatcctc accggagaat ctgtgtctgt tatcaagcac 300 accgactctgtgccagatcc acgcgctgtt aaccaggaca agaagaattg tctgttctcg 360 ggaaccaatgtcgcatctgg aaaggctcgt ggaatcgtct tcggaaccgg attgaccact 420 gaaatcggaaagatccgtac cgaaatggct gagaccgaga atgagaagac accacttcaa 480 cagaagttggacgaattcgg agagcaactt tccaaggtta tctctgttat ttgcgttgct 540 gtttgggctatcaacattgg acatttcaac gatccagctc acggtggatc atgggttaag 600 ggagcaatctactacttcaa aatcgccgtt gctcttgccg tcgctgctat tccagaagga 660 cttccagctgtcatcaccac gtgccttgcc ctcggaactc gccgtatggc caagaagaac 720 gctattgtaagatcccttcc atccgtcgaa actcttggat gcacatctgt tatctgctct 780 gacaagactggaactctcac caccaaccag atgtctgtgt caaagatgtt catcgctgga 840 caagcttctggagacaacat caacttcacc gagttcgcca tctccggatc cacctacgag 900 ccagtcggaaaggtttccac caatggacgt gaaatcaacc cagctgctgg agaattcgaa 960 tcactcaccgagttggccat gatctgcgct atgtgcaatg attcatctgt tgattacaat 1020 gagaccaagaagatctacga gaaagtcgga gaagccactg aaactgctct tatcgttctt 1080 gctgagaagatgaatgtttt cggaacctcg aaagccggac tttcaccaaa ggagctcgga 1140 ggagtttgcaaccgtgtcat ccaacaaaaa tggaagaagg agttcacact cgagttctcc 1200 cgtgatcgtaaatccatgtc cgcctactgc ttcccagctt ccggaggatc tggagccaag 1260 atgttcgtgaagggagcccc agaaggagtt ctcggaagat gcacccacgt cagagttaac 1320 ggacaaaaggttccactcac ctctgccatg actcagaaga ttgttgacca atgcgtgcaa 1380 tacggaaccggaagagatac ccttcgttgt cttgccctcg gaaccatcga taccccagtc 1440 agcgttagcaacatgaacct cgaagactct acccaattcg tcaaatacga acaagacatc 1500 acatttgtcggagtcgtcgg aatgcttgac cccccaagaa ctgaagtttc ggactcgatc 1560 aaggcttgtaaccacgctgg aatccgtgtc atcatgatca ccggagacaa caagaacacc 1620 gctgaggctatcggaagaag aatcggactc ttcggagaga acgaggatac cactggaaaa 1680 gcttacactggacgtgaatt tgacgatctt ccaccagagc aacaatctga agcctgccgc 1740 agagctaagcttttcgcccg tgtcgagcca tctcacaagt ccaagattgt cgatatcctt 1800 caatcccagggagagattac tgctatgacc ggagacggag tcaacgacgc tccagctttg 1860 aagaaggccgaaatcggaat ttctatggga tcaggaactg ctgtcgccaa gtctgcatct 1920 gaaatggttcttgctgacga taacttcgca tccattgtgt ctgctgtcga agaaggacgt 1980 gctatttacaacaacatgaa acaattcatc agatatctca tctcatctaa cgtcggagaa 2040 gtcgtctccatcttcatggt cgccgcactc ggaattccag aggctctcat tccagttcaa 2100 cttctctgggttaacttggt cactgacggt cttccagcca ctgctctcgg attcaatcca 2160 ccagatcttgacattatgga cagacatcca cgttcagcca acgatggact catctctgga 2220 tggctcttcttcagatatct tgctgtcgga a 2251 17 22 DNA Artificial Sequence Descriptionof Artificial Sequence primer oGK21 17 tggactcatc tctggatggc tc 22 18 39DNA Artificial Sequence Description of Artificial Sequence primer oGK2218 cttctccttt actcatcaat tcgttatgta acttgtcgg 39 19 35 DNA ArtificialSequence Description of Artificial Sequenceprimer oGK23 19 gaactatacaaatagttgaa gttcttctaa ccccc 35 20 24 DNA Artificial Sequence Descriptionof Artificial Sequence primer oGK24 20 gcgtttatcc ttgattggag cttc 24 2121 DNA Artificial Sequence Description of Artificial Sequence primeroGK25 21 gaatggatcg ccgtgttgaa g 21 22 36 DNA Artificial SequenceDescription of Artificial Sequence primer oGK26 22 ttctccttta ctcatgtcgcgtttatcctt gattgg 36 23 37 DNA Artificial Sequence Description ofArtificial Sequence primer oGK27 23 gaactataca aatagaaatg acagtgctccctcaatc 37 24 23 DNA Artificial Sequence Description of ArtificialSequence primer oGK28 24 gtgggatcct ggtttgttct gag 23 25 23 DNAArtificial Sequence Description of Artificial Sequence primer SERCA P225 cgaagagcac gaagatcaga cag 23 26 19 DNA Artificial SequenceDescription of Artificial Sequence primer SERCA P8 26 gagaggcggttggtttggg 19 27 22 DNA Artificial Sequence Description of ArtificialSequence primer SERCA P4 27 ccgttcgtca tccttctcat tc 22 28 20 DNAArtificial Sequence Description of Artificial Sequence primer SERCA P728 cgacagatgg accgacgagc 20 29 35 DNA Artificial Sequence Description ofArtificial Sequence primer oGK33F256V 29 caacagaagt tggacgaagtcggagagcaa ctttc 35 30 35 DNA Artificial Sequence Description ofArtificial Sequence primer oGK34F256V 30 gaaagttgct ctccgacttcgtccaacttc tgttg 35 31 57 DNA Artificial Sequence Description ofArtificial Sequence primer oGK118 31 gccagtcgga aaggtttcca aggacgacaagccagttaac ccagctgctg gagaatt 57 32 57 DNA Artificial SequenceDescription of Artificial Sequence primer oGK119 32 aattctccagcagctgggtt aactggcttg tcgtccttgg aaacctttcc gactggc 57 33 40 DNAArtificial Sequence Description of Artificial Sequence primer oGK108 33gaccgtacga aattttcagg aaaggaatgc agaaaatgcc 40 34 37 DNA ArtificialSequence Description of Artificial Sequence primer oGK109 34 ccccggccggccttactcca gtattgcagg ttccagg 37 35 30 DNA Artificial SequenceDescription of Artificial Sequence primer oGK51 35 gctctagatg gataaagtccaatacctcac 30 36 30 DNA Artificial Sequence Description of ArtificialSequence primer oGK52 36 gctctagatg gagaaagtcc aatacctcac 30 37 30 DNAArtificial Sequence Description of Artificial Sequence primer oGK55 37ggggtacctc agagaagcat cacgatgatg 30 38 35 DNA Artificial SequenceDescription of Artificial Sequence primer oGK56 38 ggggtaccat gagaagcatcacgatgatgc aaatc 35 39 6 PRT Caenorhabditis elegans 39 Lys Asp Asp LysPro Val 1 5

1. A method of identifying compounds which modulate the interactionbetween a sarco/endoplasmic reticulum calcium ATPase and phospholamban,which method comprises: exposing transgenic C. elegans which contains afirst transgene comprising nucleic acid encoding a vertebratephospholamban protein and which expresses a SERCA protein to a compoundunder test; and detecting a phenotypic, biochemical or behaviouralchange in the transgenic C. elegans indicating an increase in theactivity of the SERCA protein.
 2. A method as claimed in claim 1 whereinthe vertebrate phospholamban protein is pig phospholamban or humanphospholamban.
 3. A method as claimed in claim 1 or claim 2 wherein thefirst transgene comprises nucleic acid encoding a vertebratephospholamban protein operatively linked to a tissue-specific promoter.4. A method as claimed in claim 3 wherein the tissue-specific promoteris capable of directing gene expression in cells of the C. eleganspharynx, preferably pharynx muscle cells or capable of directing geneexpression in cells of the C. elegans vulva, preferably vulva musclecells or capable of directing gene expression in the cells of the C.elegans body wall muscles.
 5. A method as claimed in any one of claims 1to 4 wherein the transgenic C. elegans contains a second transgenecomprising nucleic acid encoding the said SERCA protein.
 6. A method asclaimed in claim 5 wherein the second transgene comprises nucleic acidencoding the said SERCA protein operatively linked to the promoterregion of a SERCA gene.
 7. A method as claimed in claim 6 wherein saidpromoter region is the promoter region of the C. elegans SERCA gene. 8.A method as claimed in any one of claims 5 to 7 wherein the SERCAprotein is a vertebrate SERCA protein.
 9. A method as claimed in claim 8wherein the vertebrate SERCA protein is pig SERCA1a, pig SERCA1b, pigSERCA2a, pig SERCA2b, Pig SERCA3, human SERCA1a, human SERCA1b, humanSERCA2a, human SERCA2b or human SERCA3.
 10. A method as claimed in anyone of claims 5 to 7 wherein the SERCA protein is a fusion between a C.elegans SERCA protein and a vertebrate SERCA protein.
 11. A method asclaimed in any one of claims 1 to 10 wherein the vertebratephospholamban protein is expressed in at least cells of the pharynx andpreferably the pharynx muscle cells of said transgenic C. elegans.
 12. Amethod as claimed in claim 11 wherein the step of detecting aphenotypic, biochemical or behavioural change in the transgenic C.elegans indicating an increase in the activity of the vertebrate SERCAprotein comprises detecting a change in the pharynx pumping efficiencyof the C. elegans.
 13. A method as claimed in claim 11 wherein thetransgenic C. elegans contains a further transgene comprising a promoterwhich is capable of directing gene expression in the muscles of the C.elegans pharynx operatively linked to nucleic acid encoding anapoaequorin protein.
 14. A method as claimed in claim 13 wherein thepromoter is the C. elegans myo-2 promoter or the C. elegans SERCApromoter.
 15. A method as claimed in claim 13 or claim 14 wherein thestep of detecting a phenotypic, biochemical or behavioural changeindicating an increase in the activity of the vertebrate SERCA proteincomprises comparing the level of apoaequorin luminescence in the absenceof the compound under test and the level of apoaequorin luminescence inthe presence of the compound under test.
 16. A method as claimed in anyone of claims 1 to 10 wherein the vertebrate phospholamban protein isexpressed in at least cells of the C. elegans vulva and preferably vulvamuscle cells of said transgenic C. elegans.
 17. A method as claimed inclaim 16 wherein the step of detecting a phenotypic, biochemical orbehavioural change in the transgenic C. elegans indicating a change inthe activity of the vertebrate SERCA protein comprises comparing thegrowth rate of the C. elegans in the absence of the compound under testand the growth rate of the C. elegans in the presence of the compoundunder test.
 18. A method as claimed in claim 16 wherein the step ofdetecting a phenotypic, biochemical or behavioural change in thetransgenic C. elegans indicating a change in the activity of thevertebrate SERCA protein comprises comparing the turbidity of the C.elegans in the absence of the compound under test and the turbidity ofthe C. elegans in the presence of the compound under test.
 19. A methodas claimed in claim 16 wherein the step of detecting a phenotypic,biochemical or behavioural change in the transgenic C. elegansindicating a change in the activity of the vertebrate SERCA proteincomprises detecting a change in the egg laying behaviour of the C.elegans.
 20. A method as claimed in claim 16 wherein the step ofdetecting a phenotypic, biochemical or behavioural change in thetransgenic C. elegans indicating a change in the activity of thevertebrate SERCA protein comprises detecting a change in the number ofprogeny produced by the C. elegans.